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ABSTRACT 
ATP binding cassette (ABC) transporters constitute one of the largest families of transport 
proteins. The occurrence of multidrug resistance (MDR) in human cancer cells has been 
correlated with the over expression of human ABC, P-glycoprotein (Pgp). Streptomyces 
peucetius produces two anticancer agents, doxorubicin and daunorubicin, that belong to the 
anthracycline family of antibiotics.   The organism is self-resistant to the potent effects of the 
antibiotics it produces due to the action of an efflux pump, DrrAB. Both Pgp and DrrAB carry 
out similar functions, but in two different cell types. An understanding of the bacterial drug 
transporter DrrAB is thus expected to help in obtaining a better understanding of the function 
and evolution of the multidrug transporter P-glycoprotein.  
In DrrAB, the catalytic and membrane domains are present on separate subunits, DrrA 
and DrrB respectively. How the catalytic ATP-binding domains and the membrane domains in 
transporters interact with each other, or how energy is transduced between them, is not well 
understood. We introduced several single cysteine substitutions in DrrB and then by using a 
cysteine to amine hetero-bifunctional cross-linker showed that DrrA interacts predominantly 
with the N-terminal cytoplasmic tail of DrrB.  Within this region of DrrB, we also identified a 
sequence with similarities to the EAA motif found in importers of the ABC family of proteins, 
thus leading to the proposal that the EAA or the EAA-like motif may be involved in forming a 
generalized interface between the ABC and the TMD of both uptake and export systems.  By 
using a combination of approaches, including point mutations and disulfide cross-linking 
analysis, we show here that the Q-loop region of DrrA plays an important role in dimerization of 
DrrA as well as in interactions with DrrB.  Furthermore, we also show that the interaction of the 
Q-loop with the N-terminus of DrrB is involved in transmitting conformational changes between 
DrrA and DrrB. The scope of the present study further extends into identifying the factors 
involved in the biogenesis of the DrrAB pump. We have identified two accessory proteins 
namely, FtsH and GroEL that may be involved in proper folding and assembly of the transporter. 
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INTRODUCTION 
  2 
Bacteria of the genus Streptomyces are gram positive spore-bearing soil bacteria that belong to 
the family Streptomycetece and resemble filamentous fungi. Members of this family produce 
various antibiotics and have been well studied and documented in this aspect.  Streptomyces 
peucetius produces two clinically important anti-tumor agents, doxorubicin (Dox) and 
daunorubicin (Dnr) and is itself resistant to the potent action of these drugs (1). Resistance to 
Dox and Dnr in S. peucetius is conferred by the resistance genes drrAB (1).  This locus was 
initially cloned into S. lividans by Guilfoile and Hutchinson and was found to be sufficient to 
confer resistance to these drugs in the otherwise sensitive species S. lividans (1).  Sequence 
analysis suggested that this locus consists of two ORFs, drrA and drrB, both of which were 
shown to be required for resistance in S. lividans (1).  The same study also showed that the 
resistance genes reside in the dnr gene cluster (Figure 1).  
 
 
Journal of Industrial Microbiology & Biotechnology (1999) 23, 647–652 
FIGURE 1: Physical map of the dnr gene cluster in Streptomyces peucetius. The cluster 
contains genes involved in the synthesis, regulation and resistance to the antibiotics Dox and 
Dnr 
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The dnr gene cluster contains genes involved in the synthesis, regulation and resistance to 
the antibiotics Dox and Dnr. The onset of production of the resistance determinants corresponds 
to the onset of the production of the secondary metabolites in the stationary phase of growth (1, 
2). A 2 kb DNA fragment consisting of just the drrAB genes has been sub-cloned and expressed 
in E. coli in the Kaur laboratory (3).  Nucleotide sequence of drrA and drrB suggests that they 
belong to the ABC (ATP Binding Cassette) family of proteins and bear homology to Pgp and 
other members of the ABC1 family (1). Functional analysis of the two proteins in E. coli has 
confirmed that the presence of both the proteins, DrrA and DrrB, is needed to develop resistance 
to Dox in sensitive E.coli (3).  The products of the two open reading frames have been 
characterized.  DrrA has been shown to be a 36-kDa peripheral membrane protein that binds 
ATP in a UV-catalyzed Dox-dependent manner (4).  DrrB is a 30-kDa hydrophobic protein that 
is localized to the inner membrane of E.coli (4).  A model for the membrane topology of DrrB is 
now available (5). This model suggests that DrrB contains eight transmembrane domains with 
both the N-terminal and the C-terminal ends directed in the cytoplasm. 
Preliminary studies to determine the function and stability of DrrA and DrrB have shown 
that the two proteins are dependent on each other for stability and function (4).   A Western blot 
analysis of cells containing the drrB gene alone shows a dramatic reduction in the level of the 
DrrB protein (Figure 2, lane 3).   However, when DrrA is introduced into the cells in trans, the 
expression level of DrrB is restored (lane 5).   This suggests that DrrB depends on DrrA for 
maintaining its stability.   Levels of DrrA are also reduced in cells containing the drrA gene 
alone, but not as dramatically as DrrB alone (lane 1 and 2).   However, no ATP binding to DrrA 
is detected in cells containing DrrA alone, suggesting that DrrA is dependent on DrrB for 
maintaining its active conformation.   The co-dependence of DrrA and DrrB on one another 
  4 
suggests biochemical coupling between the two proteins.   Chemical cross-linking studies have 
shown that the two proteins interact with each other to form a tetramer with a stoichiometry of 
DrrA2B2 (4).    
 
 
 
 
 
 
J Biol Chem, (1998) 273, 17933-17939 
FIGURE 2: Effect of co-expression of DrrA and DrrB.  E. coli cells, co-transformed with 
pDX103 and pDX108, were induced with IPTG and lysed as described under "Experimental 
Procedures”.  The total lysates were analyzed by SDS-PAGE followed by Western blot analysis 
using anti-DrrA or anti-DrrB serum.  Lane 1, pDX108; lane 2, pDX102; lane 3, pDX103; lane 4, 
pDX101; lane 5, pDX103 and pDX108. 
 
  
Our laboratory is interested in understanding the mechanism by which the DrrAB drug 
transporter carries out efflux of Dnr and Dox antibiotics.  This is important for a variety of 
reasons - the most important being that drug resistance is an emerging clinical problem and an 
understanding of the mechanism of resistance can help in designing effective strategies to 
combat drug resistance.  Furthermore, the DrrAB system exhibits similarities with P-
glycoprotein (Pgp), an MDR protein overexpressed in cancer cells (6).  Eventhough the domain 
architecture of Pgp and DrrAB is different in that Pgp is one large protein containing 2 NBD and 
2TMD domains, while DrrAB consists of NBD and TMD present on two separate subunits 
(Figure 3), the two systems have sequence and functional similarity (7). Both belong to the ABC 
family of proteins and both carry out ATP-dependent efflux of doxorubicin. Thus, a better 
  5 
understanding the mechanism of function of DrrAB proteins and interaction between them would 
no doubt throw light on the mechanism and origin of multidrug resistance  
 
 
 
 
 
 
 
 
 
Biochemical Journal (2003) Volume 376, 313-338 
FIGURE 3: Domain architecture of ABC transporters from microorganism to man. 
 
How the catalytic ATP-binding domains and the membrane domains in transporters 
interact with each other, or how energy is transduced between them, is not well understood.  
Since the domains in the DrrAB system are present on separate subunits, it makes it an ideal 
model system for the study of interaction between the ATP-binding domains and the membrane 
domains. Previous cross-linking studies in this laboratory employed membrane-permeable and 
impermeable amine to amine cross-linkers, DSP and DTSSP, and identified a complex of DrrA 
and DrrB (4). However, using DSP and DTSSP, it was not possible to easily determine the 
regions involved in cross-linking. The goal of the present study was to directly identify the 
regions of DrrA and DrrB that are involved in interaction and in transmitting conformational 
changes between one another.  To further our understanding of interactions between DrrA and 
  6 
DrrB, and the mechanism of the DrrAB complex, the study extends into the characterization of 
accessory proteins involved in biogenesis of the DrrAB efflux pump. This dissertation comprises 
of three chapters and an in-depth introduction to each research study has been presented at the 
beginning of each chapter.   
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CHAPTER I 
 
Biochemical Characterization of Domains in the Membrane Subunit DrrB That Interact 
with the ABC Subunit DrrA: Identification of a Conserved Motif 
  9 
         ABSTRACT                         
DrrA and DrrB proteins confer resistance to the commonly used anticancer agents daunorubicin 
and doxorubicin in the producer organism Streptomyces peucetius. The drrAB locus has 
previously been cloned in Escherichia coli, and the proteins have been found to be functional in 
this host. DrrA, a soluble protein, belongs to the ABC family of proteins. It forms a complex 
with the integral membrane protein DrrB. Previous studies suggest that the function and stability 
of DrrA and DrrB are biochemically coupled. Thus, DrrA binds ATP only when it is in a 
complex with DrrB in the membrane. Further, DrrB is completely degraded if DrrA is absent. In 
the present study, we have characterized domains in DrrB that may be directly involved in 
interaction with DrrA. Several single-cysteine substitutions in DrrB were made. Interaction 
between DrrA and DrrB was studied by using a cysteine to amine chemical cross-linker that 
specifically cross-links a free sulfhydryl group in one protein (DrrB) to an amine in another 
(DrrA). We show here that DrrA cross-links with both the N- and the C-terminal ends of the 
DrrB protein, implying that they may be involved in interaction. Furthermore, this study 
identifies a motif within the N-terminal cytoplasmic tail of DrrB, which is similar to a motif 
recently shown by crystal structure analysis in BtuC and previously shown by sequence analysis 
to be also present in exporters, including MDR1. We propose that the motif present in DrrB and 
other exporters is actually a modified version of the EAA motif, which was originally believed to 
be present only in the importers of the ABC family. The present work is the first report where 
domains of interaction in the membrane component of an ABC drug exporter have been 
biochemically characterized.  
 
  10 
    INTRODUCTION       
Daunorubicin and doxorubicin, two commonly used anti-cancer drugs, are produced by the soil 
organism Streptomyces peucetius. Self-resistance to these antibiotics in S. peucetius is mediated 
by the action of two proteins, DrrA and DrrB, which are coded by the drrAB operon (1). 
Subcloning of the drrAB locus has been shown to confer doxorubicin resistance in Escherichia 
coli (2). DrrA, a peripheral membrane protein, contains one ABC-type (ATP Binding Cassette) 
(3) consensus nucleotide binding domain (NBD)1 (1, 2). It forms a complex with DrrB, which is 
localized to the inner membrane of the E. coli cells (2). Together, DrrA and DrrB are expected to 
form an ATP-dependent pump for the efflux of daunorubicin and doxorubicin, resulting in 
resistance to these antibiotics (1, 2). Interestingly, the DrrAB system bears sequence, structural, 
and functional similarities to P-glycoprotein (Pgp) found in mammalian tumor cells (1, 2, 4). 
Overexpression of Pgp in cancer cells has been implicated in the development of multidrug 
resistance to a variety of structurally unrelated drugs, including daunorubicin and doxorubicin (4, 
5). Thus, both Pgp and DrrAB carry out similar functions, but in two different cell types. An 
understanding of the bacterial drug transporter DrrAB is thus expected to help in obtaining a 
better understanding of the function and evolution of the multidrug transporter P-glycoprotein.     
Most ABC transporters are made up of four domains-two nucleotide binding domains and two 
transmembrane (TM) domains. These four domains can be present on the same molecule (Pgp 
(6), CFTR (7)), on two half-molecules (LmrA (8), Tap1 (9), Tap2 (10), HlyB (11), MsbA (12)), 
or on completely separate polypeptides (DrrAB (13), BtuCD (14)). In DrrAB, the catalytic and 
membrane domains are present on separate subunits, which are expected to form a tetramer 
consisting of two identical subunits of DrrA and two of DrrB (13). Although present on separate 
subunits, the two domains of DrrAB show a strong dependence on each other for stability and 
  11 
function (13). Thus, DrrA, the nucleotide binding subunit, binds ATP or GTP in a doxorubicin-
dependent manner only if it is in a complex with DrrB (13). Further, DrrB is completely 
degraded if DrrA is not simultaneously expressed (13). These characteristics of DrrAB make it 
an ideal model system to study interactions between the ABC domain and the TM domain of 
ABC transporters and to identify specific regions of interaction.                     
How the catalytic ATP-binding domains and the membrane domains in transporters interact with 
each other, or how energy is transduced between them, is not well understood. An effort is 
currently underway to better understand these interactions in different ABC transporters, 
including medically relevant transporters Pgp (6) and CFTR (Cystic Fibrosis Transmembrane 
Regulator) (7, 15, 16). As of now, however, not much is known about the mechanism of 
interaction between membrane domains and ABC domains in these proteins. Both Pgp and 
CFTR contain all four domains in the same molecule; thus, analysis of interactions between them 
involves subcloning of the domains (6, 7), which may not be conducive to retaining proper 
structure and function. Since the domains in the DrrAB system are present on separate subunits, 
we have taken advantage of this characteristic, in the present study, to study interaction by a 
heterobifunctional cysteine to amine cross-linking approach. Previous cross-linking studies in 
this laboratory employed membrane-permeable and -impermeable amine to amine cross-linkers, 
DSP and DTSSP, and identified a complex of DrrA and DrrB (13). However, using DSP and 
DTSSP, it was not possible to easily determine the regions involved in cross-linking. In the 
present study, we have used a more direct and specific approach to identify regions in DrrB that 
are physically close to DrrA and thus may be involved in an interaction with DrrA.      
DrrB protein contains a single cysteine at position 260, whereas DrrA protein contains none. A 
cysteine-less DrrB was first created by substituting a serine at position C260 by site-directed 
  12 
mutagenesis. Twenty single-cysteine substitutions were thus introduced at various positions in 
the cysteine-less DrrB. The location of the cysteine substitutions in DrrB was based on a recently 
developed topological model for DrrB (17), which suggests that DrrB consists of eight 
transmembrane domains with both the N-terminal and the C-terminal ends of the protein directed 
in the cytoplasm. To directly identify the regions of DrrB that interact with DrrA, a 
heterobifunctional cysteine to amine chemical cross-linking agent, GMBS (N-[ -
maleimidobutyryloxy]succinimide ester), was employed. Studies reported here show that DrrA 
cross-links with both the N-terminal and the C-terminal ends of DrrB, suggesting that these two 
regions may participate in interaction with DrrA. Furthermore, this study identifies a sequence 
within the N-terminal cytoplasmic tail of DrrB, which is similar to the "L-loop" motif recently 
identified in the BtuC protein involved in VitB12 uptake in E. coli (18). By crystal structure 
analysis, the L-loop motif has been shown to lie at the interface of BtuC, the membrane 
component, and BtuD, the ABC component, where it is involved in forming extensive contacts 
between the two domains. BtuCD is a binding protein-dependent import system. It has 
previously been shown that permeases belonging to this group contain an EAA motif within their 
interaction interfaces (19). A closer look at the sequence of the L-loop suggested to us that it is 
actually similar, though not identical, to the "EAA-loop" previously identified in this group of 
proteins. While the L-loop of BtuC retains several features of the EAA loop, it also shares certain 
features with the motif present in DrrB (shown in this study) and other exporters (described 
earlier (18)). The sequence analysis and the alignments presented in this article thus allow us to 
conclude that the exporters, including DrrB, LmrA, MDR1, CFTR, and MsbA, as well as the 
importer BtuC contain a conserved motif bearing the amino acid sequence GE-1..A3R/K..G7. We 
further conclude that this conserved sequence is a modified version of the EAA motif 
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E1AA3RALG7-although a significantly modified version with its own distinct features.         
The present study is the first report where interacting domains in the membrane component of a 
drug efflux system have been biochemically analyzed by using a cross-linking approach. The 
domain identified by cross-linking was found to contain an EAA-like motif previously identified 
in the interaction interfaces of importers of the ABC family. We propose that the EAA motif or a 
modified version of the EAA motif may be involved in forming a generalized interface between 
the membrane component and the ABC component of both uptake and efflux systems. The 
evolutionary implications of this finding are discussed.  
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       MATERIALS AND METHODS                            
Bacterial Strains and Plasmids: E. coli TG1 (20) and XL1 Blue (Clonetech, BD Biosciences) 
were used in this study.                                             
Media and Growth Conditions: Cells were grown in Luria Broth. Chloramphenicol was added to 
a final concentration of 20 g/mL.                                               
DNA Manipulation: The conditions for plasmid isolation, DNA endonuclease restriction 
analysis, ligation, and sequencing have been described elsewhere (20).                    
Site-Directed Mutagenesis: The cysteine residue at position 260 in DrrB in the plasmid pDx101 
was altered to a serine using a Strategene QuikChange multisite-directed mutagenesis kit (La 
Jolla, CA). The strategy involved the use of complementary primers that incorporated the change 
at the required position. The sequence of the primers used is 
 
These primers were used for polymerase chain reaction amplification using pDx101 as a 
template (2). The amplified product bearing the mutation was then transformed into XL1 blue 
competent cells (provided by the manufacturer) and plated on medium containing 
chloramphenicol. Plasmid DNA was isolated from the colonies grown on the selection plates and 
the desired mutation in the drrAB genes was verified by sequencing of DNA. Sequencing was 
carried out using ABI 377 or 3100 sequencers (Applied Biosystems) in the Core Facilities in the 
Department of Biology at the Georgia State University. The cysteine-less serine substitution 
mutant was named C260S in this study. Subsequent single cysteine substitution mutants were 
then created in the cysteine-less DrrB, C260S. Complementary primers bearing the mutation at 
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the desired location were used for each of these mutations. Primers used for making S23C 
mutation are shown here as an example: 
 
Single cysteine substitution mutants were created at amino acid positions 4, 15, 23, 35, 44, 53, 
70, 80, 92, 107, 116, 129, 149, 160, 173, 213, 236, 249, 270, and 282 in DrrB. The mutants were 
named S4C, S15C, S23C, S35C, A44C, V53C, T70C, S80C, V92C, S107C, V116C, A129C, 
T149C, A160C, V173C, S213C, S236C, T249C, A270C, and A282C, respectively.    
Doxorubicin Resistance Assay: Doxorubicin resistance assays were carried out on M9 
(Sambrook 1989) plates supplemented with 0.25% casamino acids. The plates were layered with 
4 mL of top agar (0.8% agar in M9 medium) containing the desired concentration of 
doxorubicin. Briefly 4 mL of top agar containing 0, 4, 6, 8, or 10 g/mL of doxorubicin and 1 
mM Thiamine-HCl was poured on top of M9 plates. The plates were covered with foil to prevent 
exposure to light. Doxorubicin hydrochloride was purchased from Sigma Chemicals and used 
with the necessary precautions needed for a light-sensitive chemical. A doxorubicin-sensitive 
strain of E. coli, N43 (21), was transformed with the indicated plasmids. N43 cells freshly 
transformed with the desired plasmid were grown for 8 h in 3 mL of LB with the appropriate 
antibiotics. Ten microliters of the 8 h old N43 culture from above was inoculated on the plates 
containing doxorubicin. N43 containing the plasmid pSU2718 was used as a negative control. 
The plates were then incubated at 37 C overnight, and growth was recorded after 24 h of 
incubation.                         
Fractionation of Cells into Cytosolic and Membrane Fractions: Competent E. coli TG1 cells 
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were transformed with the plasmid bearing the mutated gene. A 50 mL portion of cells 
containing the indicated plasmids was grown to mid-log phase and induced with 0.25 mM IPTG. 
Growth was continued for an additional 3 h at 37 C. The cells were spun down and 
resuspended in 1.5 mL of PBS buffer (20 mM sodium phosphate, pH 7.0) and lysed by a single 
passage through a French pressure cell at 20 000 psi. The cell lysates were then centrifuged at 10 
000g for 15 min to remove the unbroken cells. The supernatants were subsequently used to 
prepare membrane fractions by ultracentrifugation at 100 000g for 1 h. The membrane pellets 
were suspended in cross-linking buffer (20 mM sodium phosphate, 150 mM sodium chloride, 0.5 
mM EDTA, pH 7.4) and used for cross-linking of proteins.           
Heterobifunctional Cross-Linking Reaction and Western Blot Analysis: A 100 L reaction 
volume containing 250 g of cell membrane protein in the cross-linking buffer was used. GMBS 
(N-[ -maleimidobutyryloxy]sulfosuccinimide ester; 6.4 Å length), prepared in dimethyl 
sulfoxide (DMSO), was added to a final concentration of 1 mM. DMSO alone was used in the 
control samples. Where indicated, 5 mM ATP and/or 35 M doxorubicin was added into the 
reaction mix. The reaction was carried out for 1 h at room temperature in a light-protected area. 
A 25 L portion of 4 X Laemmli sample buffer was added to stop the reaction. The samples were 
mixed thoroughly and set aside for 5 min at room temperature. A 25 L portion (50 g of 
membrane protein) of the reaction mixture was then analyzed by SDS-PAGE using a 10% 
polyacrylamide gel, followed by Western blot analysis using either anti-DrrA or anti-DrrB 
antibodies. Detection was done by a chemiluminiscent assay using Immun-Star AP, BioRad 
(Hercules, CA).  
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          RESULTS                                    
Cysteine-less DrrB: Previous studies have suggested that DrrA and DrrB interact with each other 
in a very specific manner (13). This interaction is essential for the maintenance of DrrB and for 
the function of DrrA, indicating that the two proteins are biochemically coupled. The purpose of 
the present study was to analyze domains in DrrB that are involved in interaction with DrrA. A 
model for the membrane topology of DrrB is now available (17). This model suggests that DrrB 
contains eight transmembrane domains with both the N-terminal and the C-terminal ends 
directed in the cytoplasm (17). On the basis of this model, several single-cysteine substitutions in 
the proposed cytosolic as well as the transmembrane domains of DrrB were made (Figure 1). 
Cross-linking between a defined cysteine in the DrrB protein and an amine in the DrrA protein 
was analyzed. The DrrA protein contains 43 primary amines which are spread evenly over the 
entire length of the protein. Of the 43 amines, 5 are lysines, which may be preferentially 
involved in cross-linking. The lysines are present at amino acid positions 16, 46, 137, 226, and 
327 in DrrA, which contains a total of 329 residues. The cysteine to amine cross-linking 
approach was possible because DrrB protein contains a single cysteine at position 260, whereas 
DrrA protein contains none. Using site-directed mutagenesis, the single cysteine in DrrB was 
altered to a serine residue. To rule out if the C260S mutation has an adverse effect on interaction 
between DrrA and DrrB, the levels of DrrA and DrrB in the mutant C260S were compared to 
those in the wild type C260 (Figure 2). Comparable levels of DrrA (Figure 2A) and DrrB (Figure 
2B) were seen in the membrane fractions prepared from the wild type and the mutant cells. Since 
the stability of DrrA and DrrB is a good indicator of interaction (13), these results suggest that 
the cysteine-less DrrB is not affected in its interaction with DrrA.  Single Cysteine Substitution 
Mutants of DrrB. Twenty single cysteine substitution mutants in DrrB were then created using 
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C260S as the starting material (Figure 1). The residues chosen for cysteine substitutions were 
selected so that they would result in conservative changes. Western blot analysis of the cell 
membranes showed that both DrrA (Figures 3-5) and DrrB (not shown) are expressed in cells 
containing cysteine substitution mutants. Some amount of variation in the amounts of DrrA and 
DrrB was seen in the substitution mutants, as compared to the wild-type cells (Figures 3-5). 
Experimental variation in the levels of DrrA or DrrB is also routinely seen in the wild-type cells, 
as expected in a physiological system.                                                                                        
Secondary Structure Analysis of the Cysteine Substitution Mutants: The membrane topology of 
the DrrB protein has been determined experimentally, and it has been shown to contain eight 
transmembrane helices with both the N- and the C-terminal tails in the cytoplasm (17). The 
predicted secondary structure of DrrB was determined by the Chou-Fasman method. By this 
method, the DrrB protein is seen to contain two helical stretches in regions of DrrB that are 
exposed to the cytoplasm. The first helical region, extending from amino acids 24 to 53, lies 
within the N-terminal cytoplasmic tail, and the second lies in the third cytoplasmic loop (C3), 
extending from amino acids 226-248. Since the Chou-Fasman method does not predict 
transmembrane helices, the secondary structure prediction of DrrB was verified by the PROF 
method employed by the Predictprotein server (www.predictprotein.org). PROF not only 
predicted the helices corresponding to the transmembrane domains of DrrB, but more 
significantly, it predicted the same two helical segments as were shown by the Chou-Fasman 
method in the cytoplasmic regions of DrrB. These regions lie between amino acids 32 and 49 in 
the N-terminal domain and between 222 and 245 in the C-terminal domain. Secondary structure 
prediction was also done for the 20 single-cysteine substitutions and other point mutants used in 
this study. Three out of 20 cysteine substitution mutants showed some change in the secondary 
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structure of the protein by the Chou-Fasman prediction, while the others remained unchanged. 
Those with the altered secondary structure include S35C, A44C, and S236C. Of these, only 
S236C was seen to affect doxorubicin resistance phenotype, as described below. The PROF 
method of prediction showed no significant change in the secondary structure of any of the 
substitutions or point mutants used in the study.                                                      
Doxorubicin Resistance: To determine if cysteine substitutions in DrrB have an effect on the 
function of the transporter, doxorubicin resistance assays were carried out. Most of the strains 
containing single-cysteine substitutions showed levels of doxorubicin resistance comparable to 
that of the wild-type strain (Table 1 ), suggesting that the function of the complex is not 
significantly affected by the single-cysteine substitutions constructed in this study. However, a 
few substitutions, including V53C, T70C, V92C, A129C, S236C, and S249C, showed a decrease 
in resistance to doxorubicin (Table 1). The possible significance of these observations is 
discussed later.                                
Heterobifunctional Cross-Linking: Heterobifunctional cross-linking using GMBS was performed 
between the 20 single cysteine substitution mutants of DrrB (as well as the wild-type C260) and 
DrrA. GMBS is an NHS-ester cross-linker. It interacts with a free sulfhydryl group, provided by 
a cysteine residue on one arm and an amine residue on the other, thus forming a cross-linked 
product. The N-terminal mutant S23C was the first mutant where a cross-linked product of DrrA 
and DrrB was identified (Figure 3). Western blot analysis of the cross-linked sample identified a 
species of about 60 kDa when probed with either anti-DrrA (Figure 3B, lanes 2-5) or anti-DrrB 
(Figure 3D, lanes 2-5) antibodies. On the basis of its size, this species would correspond to one 
subunit of DrrA and one subunit of DrrB. Cross-linking could be seen at GMBS concentrations 
as low as 0.2 mM (Figure 3B,D, lane 2). No significant increase in the cross-linking efficiency 
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was observed when higher concentrations of GMBS were used (Figure 3B,D, lanes 2-5); 
however, at concentrations higher than 2 mM, a significant drop in the intensity of the 60 kDa 
species with a concomitant increase in the higher species with molecular mass greater than 200 
kDa was seen (not shown). Since high concentrations of the cross-linker can result in nonspecific 
aggregates, the maximum concentration of GMBS used in this study was 1 mM.         
The 60 kDa cross-linked species did not appear in the cysteine-less (C260S) sample on addition 
of the cross-linker (Figure 3A,C) or in the S23C control sample where DMSO alone was added 
instead of the cross-linker (Figure 3B,D, lane 1). To further verify if the same cross-linked 
species was detected by both anti-DrrA and anti-DrrB antibodies, a lane containing the cross-
linked S23C sample was spliced vertically into halves. Each half was probed with either the anti-
DrrA or the anti-DrrB antibodies. The reaction was developed by the chemiluminescence assay, 
and the halves of the nitrocellulose membrane were then aligned with the help of internal protein 
markers. Results in Figure 3E show that the same cross-linked species reacted with both 
antibodies, suggesting that it consists of both DrrA and DrrB.          
Both anti-DrrA and anti-DrrB antibodies were also seen to cross-react with some other proteins 
nonspecifically (Figure 3). This is not unexpected, since the cross-linking experiments reported 
here are carried out with the cell membrane preparations containing many other proteins in 
addition to DrrA and DrrB. Furthermore, the antibodies used for detection of the cross-linked 
species are polyclonal in nature, thus resulting in cross-reactivity with certain other epitopes (2). 
The addition of the cross-linker also appeared to change the mobility of some of these unrelated 
proteins. For example, a 43 kDa protein picked up nonspecifically with the anti-DrrA antibody 
(Figure 3B, lane 1) is decreased or is not seen in the cross-linked samples (Figure 3B, lanes 2-5). 
It should be pointed out that the disappearance of the 43 kDa band happens in all the samples, 
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irrespective of the presence (S23C) or absence (C260S) of a cysteine in DrrB (Figure 3A). Since 
the 60 kDa cross-linked species is not seen in C260S (even though the 43 kDa band disappears), 
it clearly indicates that the cross-linked species seen in S23C is not the result of cross-linking 
between DrrB and this 43 kDa unrelated protein. Thus, the 43 kDa protein cross-links with 
another unknown protein in the membrane. Since our focus in this study is on specific cross-
linked species of DrrA and DrrB, further analysis of the 43 kDa protein was not carried out. 
S23C, which showed a specific 60 kDa cross-linked species of DrrA and DrrB (described 
above), was used as a positive control in further cross-linking experiments. The remaining 19 
cysteine substitution mutants and the wild-type C260 were analyzed for the cross-linked product 
of DrrA and DrrB by Western blot analysis using both antibodies; however, only the blots 
obtained with the anti-DrrA antibody are shown (Figures 4 and 5). As seen with S23C, all the 
other cysteine substitution mutants tested in the N-terminal tail, S4C, S15C, S35C, and S44C, 
also showed the appearance of the 60 kDa species on cross-linking with GMBS by Western blot 
analysis (Figure 4A,B). The effect of addition of ATP (Figure 4A) or doxorubicin on cross-
linking was also determined. No significant effect of addition of either substrate alone or 
together on cross-linking was observed (not shown). Analysis of the mutants in TM1 (V53C and 
T70C) and TM2 (V92C and S107C) also showed the 60 kDa cross-linked species containing 
DrrA and DrrB (Figure 4B). However, S80C, a cysteine substitution in the first periplasmic loop 
(P1), did not show cross-linking with DrrA (not shown). V116C located in the first cytoplasmic 
loop also showed cross-linking with DrrA (Figure 4B). Analysis of mutants in TM's 3, 4, 5, and 
6 and the intervening cytoplasmic loops C2 and C3 did not show the 60 kDa cross-linked species 
(Figure 5A,B). Wild-type DrrB, which according to the topological model contains residue C260 
in the seventh transmembrane domain, cross-linked with DrrA (Figure 5C), although another 
  22 
substitution mutant, S249C, also in the seventh transmembrane domain, did not cross-link with 
DrrA (Figure 5B). Finally, both A270C in the eighth transmembrane domain (Figure 5C) and 
A282C at the C-terminal end of DrrB showed cross-linked products with DrrA (Figure 5C). 
Together, the chemical cross-linking data presented above show that DrrA cross-links with both 
the N-terminal and the C-terminal domains of the DrrB protein, suggesting that these regions 
may be involved in interaction. At the N terminus, the interaction involves the first 50 amino 
acids of the N-terminal cytoplasmic tail and includes the first and second transmembrane 
domains extending up to the first cytoplasmic loop of the DrrB protein. At the C-terminal end, 
the interaction between DrrA and DrrB involves the seventh and the eighth transmembrane 
helices of DrrB and it extends to the short cytosolic C-terminal tail. The intensity of the cross-
linked species varies, depending on the location of the cysteine in the DrrB protein. The best 
cross-linking was seen with cysteines in the N-terminal cytosolic tail, suggesting that this may be 
the major site of interaction with DrrA.                      
Identification of a Conserved Motif in DrrB: As described above, the Chou-Fasman and the 
PROF methods of secondary structure prediction showed that the DrrB protein contains two 
helical stretches that are present in regions exposed to the cytoplasm. The first helical region, 
extending from amino acids 24 to 53, lies within the N-terminal cytoplasmic tail and is part of 
the N-terminal domain that cross-links with DrrA; the second lies in the third cytoplasmic loop 
(C3), extending from amino acids 226 to 248. On further analysis, it was found that the helical 
region present in the N-terminal cytoplasmic tail of DrrB contains an amino acid sequence 
similar to the L-loop motif present in BtuC (18), which is the membrane component of the 
BtuCD system involved in VitB12 uptake in E. coli (Figure 6). The L-loop in BtuC is present in 
a helical stretch of the cytoplasmic loop between TM6 and TM7. On the basis of the crystal 
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structure of the BtuCD complex, the L-loop of BtuC forms extensive contacts with the ABC 
component, BtuD. It has also been previously suggested that the L-loop of BtuC shows similarity 
to a certain sequence in the first cytoplasmic loop of exporters, including the drug exporters 
MDR1 and LmrA, the lipid exporter MsbA, and the chloride channel CFTR (18), all members of 
the ABC superfamily.                                                              
An alignment of the N-terminal region of DrrB with the L-loop in BtuC and several other export 
and import proteins is shown in Figure 6. This alignment is different from that reported earlier by 
Locher et al. (18); thus, a clarification is needed at this point about the basis used for the 
alignment shown in Figure 6 in this study as well as about the relationship between the sequence 
of the L-loop (18) and the EAA-loop (19). Even though Locher et al. stated that there is a limited 
similarity of the L-loop of BtuC with the EAA-loop (18) of the binding protein-dependent 
importers (19), their sequence alignments did not reflect such a similarity. The alignment shown 
in Figure 6 in the present study uses the sequence analysis carried out by Saurin et al. (22) as the 
basis for the identification of the EAA-loop motif. In the analysis carried out by Saurin et al., 61 
integral membrane proteins belonging to the binding protein dependent importers were classified 
on the basis of the similarities between their EAA motifs. It was shown that these proteins can be 
classified into eight clusters. The sequences belonging to the main cluster were called the "EAA 
cluster". Members of this cluster contain conserved sequences almost identical with the 
E1AA3...G7...I.LP motif; however, other clusters show some differences compared to the original 
EAA motif. Within the EAA motif, the central part A3RALG7 is the most conserved-of these, the 
flanking A3 and G7 being highly conserved and the middle residues RAL less conserved (22). 
According to this classification (22), BtuC is assigned to the cluster of iron-siderophore 
transporter proteins, which contain the central A3...G7 sequence; however, they lack the E residue 
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at position 1 and instead contain an E or a D at position -1 (Figure 6). We have based our 
alignment shown in Figure 6 on the information described above. Since BtuC contains a well-
defined A3...G7 central domain, we have placed the A of the central domain A...G of BtuC at 
position 3 as described in (22). Thus, the E in BtuC falls in the -1 position, as for the members of 
the iron-siderophore cluster. Once BtuC was thus properly aligned with the EAA domain of 
other importers, DrrB and other exporters were then aligned with BtuC to obtain the alignment in 
Figure 6.                            
As seen in BtuC, the drug exporters, including DrrB, LmrA, MDR1 (N-terminal domain), and 
MDR1 (C-terminal domain), and other exporters shown in Figure 6 also contain the E residue at 
the -1 position and a somewhat less conserved A3...G7 central domain. The G at position 7 in the 
exporters does not seem to be very highly conserved; however, this group of proteins, along with 
BtuC, contains a highly conserved G at the -2 position and a positively charged residue R/K at 
position 4, which may be derived from the central domain A3RALG7 of the original EAA motif. 
Thus, it appears that the conserved sequence in DrrB and other exporters also bears a similarity 
to the EAA domain. From the sequence analysis described above and the alignment shown in 
Figure 6, we conclude that DrrB and other exporters contain a conserved motif bearing the 
sequence GE-1..A3R/K..G7, which appears to be a modified version of the original EAA motif 
(E1AA3RALG7). Furthermore, the motif present in the BtuC protein, a binding protein dependent 
importer, has characteristics of both the EAA motif of importers and the motif present in the 
exporters.                                 
Site-Directed Mutagenesis of Residues in Domains of DrrB That Cross-Link with DrrA: To 
determine if residues within the interaction domains, identified by chemical cross-linking, are 
important for the function of the DrrB protein, conservative changes in certain residues in each 
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domain were made. These changes include S23A, G25A, E26D, and S35A in the N-terminal 
domain and C260A and A270S in the C-terminal domain. Doxorubicin resistance assays showed 
that S23A, G25A, and E26D mutations in the N-terminal domain confer sensitivity to between 4 
and 6 g/mL of doxorubicin while the cells containing the wild-type DrrA and DrrB grow up to 
8-10 g/mL of doxorubicin (Table 2 ). Since S35A mutation in the N-terminal domain and 
C260A and A270S in the C-terminal domain showed no change in the doxorubicin resistance 
phenotype as compared to the wild type, nonconservative mutations of these three residues, 
including S35I, C260E, and A270Y, were created. S35I mutation conferred doxorubicin 
sensitivity, while cells containing C260E and A270Y still remained relatively unaffected (Table 
2). Protein expression analysis by SDS-PAGE showed that most mutations, except S23A, S35A, 
and A270Y show varying degrees of reduction in the levels of DrrA and DrrB. The most severe 
reduction in the levels of both DrrA and DrrB is seen with S35I mutation (Figure 7). G25A and 
E26D also showed significantly reduced levels of DrrA and DrrB, although these are less 
affected as compared to S35I. No significant change in the predicted secondary structure of any 
of the mutated proteins was seen by the Chou-Fasman or by the PROF method of secondary 
structure prediction.  
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     DISCUSSION                       
The aim of the present study was to characterize domains in the DrrB protein that are involved in 
interaction with the ABC component DrrA. It has previously been shown that the DrrA and DrrB 
proteins are biochemically coupled for their function and stability, although they form separate 
subunits in the transporter (13). To understand how these two proteins regulate the stability and 
function of each other and result in the formation of a functional transporter, it is necessary to 
understand their molecular interactions. The strategy employed to study interaction between 
DrrA and DrrB made use of a cysteine to amine cross-linking approach. This study was 
facilitated by the availability of a model for the membrane topology of DrrB (17). Thus, it was 
possible to introduce cysteine residues in DrrB at the potential sites of interaction with DrrA. 
Since DrrA is a soluble protein, the sites of interaction are expected to lie in the domains of DrrB 
exposed in the cytoplasm. Cysteine-less DrrB was first created by replacing the single cysteine in 
DrrB at position 260 with a serine residue. Twenty single cysteine substitution mutants were then 
created at desired locations in the cysteine-less DrrB (Figure 1). Cross-linking between DrrA and 
DrrB was then carried out by using the chemical cross-linker GMBS, which enables the 
formation of a cross-link between a primary amine in one protein (DrrA) and a free sulfhydryl 
group in another (DrrB) (23, 24).                    
Doxorubicin resistance assays showed that the cysteine-less DrrB C260S as well as most of the 
single cysteine substitutions in DrrB did not affect the function of the transporter. Six (V53C, 
T70C, V92C, A129C, S236C, S249C) out of 20 substitutions created in this study, however, 
showed varying levels of doxorubicin-sensitive phenotype (Table 1). All of the affected residues, 
except S236C, lie in the predicted membrane spanning helices of DrrB. Both DrrA (Figures 4 
and 5) and DrrB (not shown) are still expressed in all of the six strains. Secondary structure 
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analysis by the Chou-Fasman method showed that five (V53C, T70C, V92C, A129C, S249C) of 
these six mutants, which resulted in doxorubicin sensitivity, showed no change at all in their 
predicted secondary structure, the exception being S236C, which showed a split in the helical 
stretch predicted between residues 226 and 248 in the C terminus of DrrB. Thus, we can 
conclude that doxorubicin sensitivity in V53, T70, V92, A129, and S249C is not the result of a 
change in the secondary structure, whereas doxorubicin sensitivity in S236C may possibly be 
due to such a change. Since most of the affected residues, except S236C, occur in the membrane 
domains, it is possible that these residues may be involved in substrate recognition and thus may 
be crucial for the transport function of the DrrB protein. Studies to determine the role of these 
residues in the function of the transporter will be carried out in the future.                   
From the chemical cross-linking studies presented in this paper, we can conclude that DrrA 
cross-links with cysteines introduced in both the N-terminal and the C-terminal ends of DrrB. At 
the N-terminal end, the best cross-linking is seen with residues in the N-terminal cytoplasmic 
tail, even though it extends to residues in the first and second transmembrane domains and the 
first cytoplasmic loop. Interaction at the C-terminal end includes the seventh and the eighth 
transmembrane domain as well as the short C-terminal cytoplasmic tail of DrrB. It is intriguing 
that DrrA also cross-links with residues in the transmembrane domains of DrrB. This might 
indicate that DrrA embeds itself into the membrane during its interaction with DrrB. A similar 
phenomenon has been observed with other peripheral membrane proteins involved in transport, 
most significantly with SecA (25). It has been shown that some part of SecA is permanently 
embedded in the membrane (26-28) and that it may also play a significant role in the formation 
of the channel for the secretion of proteins (25).            
Two alternate explanations (shown in the model in parts A and B of Figure 8) can account for the 
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observation that DrrA cross-links simultaneously with both the N- and C-terminal ends of DrrB. 
The models shown in Figure 8 depict the complex of DrrA and DrrB as a tetramer. On the basis 
of the cross-linking studies carried out earlier, it has been suggested that the stoichiometry of the 
functional complex of DrrAB may be A2B2 (13). Tetramers containing DrrA and DrrB were not 
seen in the present study and are not expected to form in this situation, because cross-linking 
with GMBS specifically requires a cysteine. Each subunit of DrrB has only one cysteine; thus, it 
can form a cross-link with only one subunit of DrrA. The possible mechanism of interaction 
between DrrA and DrrB by each of these models can be explained as follows (1). According to 
the model in Figure 8A, one subunit of DrrA binds to the N terminus of one subunit of DrrB and 
to the C terminus of the other subunit (2). According to the model in Figure 8B, the halves of a 
subunit of DrrB fold upon each other such that the N- and C-terminal ends of DrrB are close to 
each other, and one subunit of DrrA is then able to interact with both ends simultaneously. We 
currently favor the second model (Figure 8B), because suppressor analyses presently being 
carried out in this laboratory suggest that the N- and the C-terminal ends of DrrB may be on the 
same interface (unpublished results). However, further biochemical and genetic analyses are 
required to clearly determine whether the interaction between DrrA and DrrB occurs by the 
mechanism depicted in model A or B in Figure 8. It will also be important in future studies to 
determine if a single region in DrrA interacts with both termini in DrrB or whether the 
interaction with DrrB occurs to two separate domains in DrrA. Even though the cross-linking 
seen in this study is likely to occur between subunits within a tetramer, the possibility of cross-
linking between tetramers cannot be ruled out. Both intra- and intermolecular cross-linking 
between cysteines in Pgp, where all four domains are present in a single molecule, has been seen 
(29). However, DrrA and DrrB form separate subunits that are held together by noncovalent 
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interactions within a tetramer of DrrA2B2; thus, at this time it is not possible to distinguish 
between cross-links within a tetramer vs those between tetramers.  Crystal structure information 
for three ABC transporters, including E. coli BtuCD, E. coli MsbA, and V. cholera MsbA, has 
recently become available (18, 30, 31). This information provides valuable insights into the 
structure of the complex and into the domains involved in interaction between the membrane 
component and the ABC component in these systems. Interestingly, we find that present within 
the N-terminal domain of DrrB, which shows cross-linking with DrrA, is a sequence which has 
significant similarity to a sequence in the "L-loop" motif recently identified in BtuC by crystal 
structure analysis (18) (Figure 6). According to the crystal structure of the BtuCD complex, the 
L-loop in BtuC forms extensive contacts with the ABC component BtuD. It has also been 
reported that the sequence of the L loop bears local similarity to a sequence present in the first 
cytoplasmic loop of drug exporters, MDR1 and LmrA, and the lipid exporter, MsbA, and to the 
fourth cytoplasmic loop in CFTR (18). In the present study, we find similarity of the L-loop to a 
sequence in the N-terminal cytoplasmic tail of DrrB and biochemically demonstrate that this 
region may be involved in interaction with DrrA. In both DrrB and BtuC, this sequence lies in a 
helical stretch in a cytoplasmic domain of the protein; in DrrB, it is present in the N-terminal 
cytoplasmic tail, while in BtuC, it is present in the cytoplasmic loop between TM6 and TM7 
(18).                                           
From the analysis carried out in this study (Figure 6), we conclude that the L-loop of BtuC is 
actually similar to the EAA loop of other importers. We further conclude that DrrB and other 
exporters (as well as the importer BtuC) contain a conserved motif with the sequence GE-
1..A3R/K..G7 and that it is actually a modified version of the original EAA motif (E1AA3RALG7) 
present in the binding protein dependent permeases. Our results thus indicate for the first time 
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that the EAA motif or a modified version of this motif may be present at the interaction 
interfaces in both uptake and efflux systems, suggesting that the sequences involved in 
interaction are derived from an ancestor before the importers and exporters of the ABC family 
might have diverged.                                                     
A conserved motif, similar to the one identified in the N-terminal domain, was not identified in 
the C-terminal interacting domain of DrrB in this study. It should be mentioned, however, that a 
second helical region was identified in the third cytoplasmic loop, between residues 226 and 248, 
of DrrB. It is possible that, in the three-dimensional structure, this region (extending up to the C-
terminal end of DrrB) may actually lie close to the conserved motif present in the N-terminal 
domain of DrrB and thus may contribute to forming the interface with DrrA, as is indicated by 
the cross-linking data (Figure 5C). Such architecture for DrrB would also be suggested by the 
model in Figure 8B. However, further biochemical and genetic studies are needed to answer 
some of these questions. Mutagenesis of certain residues in and around the conserved motif in 
the N terminus of DrrB, including S23A, G25A, E26D, and S35I, resulted in sensitivity to 
doxorubicin, although mutagenesis of C260 and A270 in the C terminus did not confer 
doxorubicin sensitivity significantly. These findings indicate that the motif in the N terminus is 
required for the function of the DrrB protein, whereas the domain in the C terminus may not be 
directly involved in function but may be at the same interface of interaction, as was suggested 
above. G25A, E26D, and S35I mutations also resulted in reduced levels of DrrA and DrrB. Since 
the stability of DrrB is known to be dependent on its interaction with DrrA, such a phenotype 
might indicate a direct role for these residues in interaction between DrrA and DrrB. Second-site 
suppressor analysis of the S23A, G25A, E26D, and S35I mutations will be carried out in the 
future to verify if these residues are indeed directly involved in interaction with DrrA, as is 
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suggested by the cysteine cross-linking studies reported here. Mutagenesis of certain residues in 
the conserved motif in MDR1 was also previously shown to result in loss of drug resistance (32); 
however, these residues were never biochemically shown to be directly involved in interaction 
with the ABC domain of MDR1. The only system where biochemical characterization has 
previously been carried out is the maltose uptake permease, where a typical EAA-loop (33), 
present in the membrane subunits MalF and MalG, has been shown to be involved in interaction 
with MalK by chemical cross-linking studies (34).                                                 
In summation, this study identifies two domains in DrrB that may be involved in interaction with 
DrrA and identifies a motif in the N-terminal cytoplasmic tail of DrrB. This motif has similarities 
to the EAA motif of binding protein dependent importers and the L-loop motif of BtuC. Other 
interactions between DrrA and DrrB, if present, could not be identified by the strategy employed 
in this study. Further studies, including the crystal structure analysis of the complex, would be 
required to identify other interactions and to determine the overall structure of the complex. Not 
only is the present study important for understanding the mechanism of interaction and function 
of the DrrAB complex, but it is also a necessary step toward elucidation of the temporal 
sequence of events leading to the biogenesis of the complex. Since the specific binding of DrrA 
to DrrB protects DrrB from proteolysis, we have previously suggested that DrrA may act like a 
chaperone to facilitate the proper assembly of the complex in the membrane (13). Furthermore, 
DrrB regulates the catalytic activity of DrrA via precise, but not yet understood, conformational 
changes. Future studies in this laboratory will identify the interacting domains in DrrA and will 
also try to unravel the concomitant conformational changes that are essential for the function of 
the complex as a transporter.  
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TABLES 
 
 
TABLE 1: Doxorubicin Resistance of E. coli N43 Cells Expressing Wild Type DrrA with 
DrrB Containing Different Cysteine Substitutionsa: a Legend: +++, very good growth; ++ 
good growth; + some growth; -, no growth.   
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TABLE 2: Doxorubicin Resistance of E. coli N43 Cells Expressing Wild-Type DrrA with 
DrrB Containing Mutations in the N-Terminal Cytoplasmic Tail or the C-Terminal Enda: a 
Legend: +++, very good growth; ++ good growth; + some growth; -, no growth.    
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1: Topological depiction of the DrrB protein in the membrane showing the 
location of various cysteine substitutions: This drawing for the topology of DrrB in the 
membrane is based on a previously published model of the DrrB protein (17). The topological 
model of DrrB, which is based on gene fusion analysis, suggests that the DrrB protein contains 
eight transmembrane helices, with both the N and the C termini in the cytoplasm. To determine 
domains in DrrB that may be involved in interaction with DrrA, various single-cysteine 
substitutions were created in the DrrB protein. The location of these cysteines in DrrB is shown. 
The cysteine substitutions were made in the N- and C-terminal tails, the cytoplasmic loops, and 
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the transmembrane domains of DrrB. S80C is the only cysteine substitution in a periplasmic 
domain. Since DrrA was found to cross-link with the residues in the N-terminal cytoplasmic tail 
as well as with residues in TM1 and TM2, S80C was created specifically to map the entire N-
terminal domain for its interaction with DrrA. The locations of various cysteines that showed 
cross-linking with DrrA are marked with rectangles.    
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FIGURE 2: Levels of DrrA and DrrB in cells containing wild-type (C260) or cysteine-less 
DrrB (C260S): E. coli cells containing C260 or C260S were induced with IPTG. The lysates 
were prepared by French press, followed by ultracentrifugation to prepare the membrane 
fractions, as described in Materials and Methods. Twenty micrograms of membrane protein was 
analyzed by SDS-PAGE on 10% gels, followed by Western blot analysis using anti-DrrA or anti-
DrrB antibodies. A chemiluminescence detection kit was used for detection of the bands. 
Migration of the standard proteins is shown on the left. (A) Probed with anti-DrrA. (B) Probed 
with anti-DrrB. Lanes: lane 1, wild-type C260; lane 2, cysteine-less mutant C260S. 
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FIGURE 3: Chemical cross-linking between wild-type DrrA and DrrB containing cysteine 
substitution C260S or S23C: The cell membrane fraction containing the DrrA and DrrB 
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(C260S or S23C) proteins was subjected to chemical cross-linking using different concentrations 
of GMBS, as described in Materials and Methods. Fifty micrograms of protein was resolved by 
SDS-PAGE, followed by Western blot analysis using anti-DrrA or anti-DrrB antibodies. The 
"minus" and "plus" at the bottom of the lanes indicate the absence and presence of the cross-
linker in the reaction, respectively. The migration of the protein standards is shown on the left. 
The location of the cross-linked species is marked as A+B. (A and B) Probed with anti-DrrA. (C 
and D) Probed with anti-DrrB. Lanes: lane 1, no GMBS; lane 2, 0.2 mM GMBS; lane 3, 0.4 mM 
GMBS; lane 4, 0.6 mM GMBS; lane 5, 0.8 mM GMBS. (E) A reaction containing the cross-
linked S23C sample was analyzed by SDS-PAGE, as described above. The prestained high-
molecular-weight protein marker from GibcoBRL was added to the sample before 
electrophoresis. The resolved proteins were transferred to the nitrocellulose membrane. The lane 
containing the S23C sample was vertically spliced into halves. Each half was then probed with 
either the anti-DrrA or anti-DrrB antibodies. Detection was done by the chemiluminescence 
method. After detection, the vertical halves were aligned using the prestained internal protein 
marker. 
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 Figure 4: Chemical cross-linking between wild-type DrrA and DrrB containing cysteine 
substitutions in the N-terminal cytoplasmic tail, the transmembrane domains TM1 and 
TM2, and the cytoplasmic loop C1: The conditions used for chemical cross-linking between 
DrrA and DrrB were same as described in the legend to Figure 3. The proteins were resolved by 
SDS-PAGE, followed by Western blot analysis using anti-DrrA antibodies. The "minus" and 
"plus" at the bottom of the lanes indicate the absence and presence, respectively, of the cross-
linker or ATP in the reaction. The migration of the protein standards is shown on the left. The 
location of the cross-linked species is marked as A+B. (A) S4C, S15C, S35C. (B) A44C, V53C, 
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T70C, V92C, S107C, and V116C. Figure 5 Chemical cross-linking between wild-type DrrA and 
DrrB containing cysteine substitutions in various transmembrane domains (TM3-TM8) or 
cytoplasmic loops C2 and C3. The conditions used for chemical cross-linking between DrrA and 
DrrB were same as described in the legend to Figure 3. The proteins were resolved by SDS-
PAGE, followed by Western blot analysis using anti-DrrA antibodies. The "minus" and "plus" at 
the bottom of the lanes indicate the absence and presence of the cross-linker in the reaction, 
respectively. The migration of the protein standards is shown on the left. The location of the 
cross-linked species is marked as A+B. (A) S23C (positive control), A129C, T149C, A160C. (B) 
V173C, S213C, S236C, S249C. (C) C260 (wild type), A270C, A282C.    
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FIGURE 5: Chemical cross-linking between wild-type DrrA and DrrB containing cysteine 
substitutions in various transmembrane domains (TM3-TM8) or cytoplasmic loops C2 and 
C3: The conditions used for chemical cross-linking between DrrA and DrrB were same as 
described in the legend to Figure 3. The proteins were resolved by SDS-PAGE, followed by 
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Western blot analysis using anti-DrrA antibodies. The "minus" and "plus" at the bottom of the 
lanes indicate the absence and presence of the cross-linker in the reaction, respectively. The 
migration of the protein standards is shown on the left. The location of the cross-linked species is 
marked as A+B. (A) S23C (positive control), A129C, T149C, A160C. (B) V173C, S213C, 
S236C, S249C. (C) C260 (wild type), A270C, A282C.   
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FIGURE 6: Alignment of the amino acid sequence of regions of DrrB, LmrA, MDR1 (N 
domain), MDR1 (C domain), CFTR (N domain), CFTR (C domain), MsbA, BtuC, HisM, 
HisQ, MalG, and MalF predicted to interact with their ABC domains/subunits: The dark 
gray regions show residues that are highly conserved, whereas the residues in light gray are less 
conserved. The first amino acid in the sequence of each protein is shown. The position of certain 
residues of the EAA domain is marked at the bottom. The E of the EAA loop is marked as 
position 1, and the E of the EAA loop in BtuC is marked as position -1.     
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FIGURE 7: Levels of DrrA and DrrB in cells containing point mutations in the N-terminal 
cytoplasmic tail or the C-terminal end of DrrB: E. coli cells containing the indicated plasmids 
were induced with IPTG. The lysates were prepared by French press, followed by 
ultracentrifugation to prepare the membrane fractions. Twenty micrograms of membrane protein 
was analyzed by SDS-PAGE on 10% gels, followed by Western blot analysis using anti-DrrA or 
anti-DrrB antibodies. A chemiluminescence detection kit was used for detection of the bands. 
Migration of the standard proteins is shown on the left. (A) anti-DrrA. (B) anti-DrrB.   
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FIGURE 8: Models showing two possible mechanisms of interaction between DrrA and 
DrrB: The complex of DrrA and DrrB is shown as a tetramer consisting of two subunits of DrrA 
(A1 and A2) and two subunits of DrrB (B1 and B2). Further, each subunit of DrrB is shown as 
containing the N half and the C half (B1N, B1C and B2N, B2C). On the basis of the observation 
that DrrA interacts with both the N- and C-terminal ends of DrrB, two alternate models for 
interaction are proposed. (A) One subunit of DrrA interacts with two subunits of DrrB 
simultaneously. Thus, DrrA1 contacts B1C and B2N. Similarly, DrrA2 contacts B1N and B2C. (B) 
One subunit of DrrA interacts with both the N- and C-termini of the same subunit of DrrB. This 
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is possible if the halves of DrrB fold upon each other, allowing the N- and C-termini to come 
together on an interface. Thus, DrrA1 binds to the interface of B1N and B1C. Similarly, DrrA2 
binds to the interface of B2N and B2C. 
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CHAPTER 2 
 
 
 
 
 
 
 
 
Conformational changes in the Q-loop region of DrrA: Role of Q-loop in Dimerization of 
DrrA and in interactions with DrrB 
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ABSTRACT 
DrrA and DrrB proteins form an ATP-dependent efflux pump for doxorubicin and 
daunorubicin in Streptomyces peucetius.  DrrA, the catalytic subunit, forms a complex with the 
integral membrane protein DrrB.  Previous studies have provided evidence for strong 
interaction between these two proteins, which was found to be critical for ATP binding to DrrA 
and for stability of DrrB.  Chemical cross-linking experiments carried out previously showed 
that in the resting state of the complex DrrA and DrrB are in contact with each other.  Use of a 
cysteine-to-amine crosslinker then allowed identification of the N-terminal cytoplasmic tail of 
DrrB (residues 1-53) as being the primary region of contact with DrrA.  In this study single 
cysteine substitutions were introduced in different domains of DrrA in a strain already 
containing S23C substitution in the N-terminal tail of DrrB.  By using different arm-length 
disulfide cross-linkers, we found that a cysteine placed in the Q-loop region of DrrA traps 
DrrA in the closed conformation.  Furthermore, the same region of DrrA was also found to 
interact with DrrB, although the A-A interaction was much more prominent than the A-B 
interaction under these conditions.  Based on additional data shown here, we propose that the 
A-B interaction identified here is specific to the closed state of DrrA and that this interaction 
identifies an important step in the communication of conformational changes between the N-
terminal region of DrrB and the Q-loop region of DrrA.  Significance of these findings in the 
mechanism of the DrrAB complex is discussed, and a model based on analyses of different 
conformations of DrrA and DrrB is presented.  
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INTRODUCTION 
Self-resistance to doxorubicin and daunorubicin, two anticancer antibiotics, in the producer 
organism Streptomyces peucetius is conferred by DrrA and DrrB proteins (1).  Together, these 
two proteins are proposed to form an ATP-driven drug pump for the export of these antibiotics, 
in the process conferring resistance (1, 2).  We are interested in understanding the mechanism 
by which this prototype drug transporter carries out efflux of these antibiotics.  This is 
important for a variety of reasons - the most important being that drug resistance is an 
emerging clinical problem and an understanding of the mechanism of resistance can help in 
designing effective strategies to combat drug resistance.  Furthermore, the DrrAB system 
exhibits similarities with P-glycoprotein (Pgp), an MDR protein overexpressed in cancer cells.  
Pgp confers multidrug resistance by carrying out ATP-dependent efflux of a variety of 
structurally unrelated drugs, including doxorubicin and daunorubicin (3).  Both DrrAB and Pgp 
also belong to the ABC family of proteins, therefore they share not only functional, but also 
sequence similarity.  Thus, the DrrAB system can shed light on the mechanism and origin of 
multidrug resistance.  
 Most ABC transporters are composed of four domains: two transmembrane (TMD) and 
two nucleotide-binding domains (NBD).  In Pgp, all four domains are present on a single 
polypeptide (3), while in DrrAB the domains are present on separate subunits (1, 2, 4-6).  The 
functional complex of DrrAB is believed to consist of two subunits of DrrA and two of DrrB 
(4).  Crystal structure data for several ABC proteins and intact ABC transporters are now 
available(7-21).  These structures depict the structure of an NBD monomer to be L-shaped 
having two arms (7-15).  Arm I contains the Walker A and Walker B motifs and is known as 
the RecA-like core ATP domain, while Arm II contains the signature motif as part of the α-
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helical domain.  A flexible Q-loop, which contains a highly conserved glutamine at its N- 
terminus, joins the RecA-like core domain to the α-helical domain.  More recent crystal 
structures, especially of E. coli MalK (17) and M. jannaschii MJ0796 proteins (8), have also 
facilitated identification of the head-to-tail dimeric intermediates of the NBDs.  In a head-to-
tail dimer, the Walker A domain of one subunit is aligned with the signature domain from the 
opposing subunit, thus producing two nucleotide binding interfaces in a dimer. This 
conformation is achieved in the presence of ATP and is referred to as the closed conformation.  
In the nucleotide-free or the open conformation, the NBDs are no longer in close proximity 
with one another.  The crystal structure of Sav1866, an MDR protein from S. aureus, however, 
implies a more limited movement of the NBD’s.  This could result from constraints on the 
structure caused by domain swapping and subunit twisting that have been noted in this 
structure (21).  The Sav1866 structure captures the protein in the ADP-bound, outward-facing 
conformation, which resembles the state after release of the substrate into the extracellular 
space.  The structure of this protein in the inward-facing conformation has so far not been 
visualized.  Although availability of structural data from many different ABC proteins (both 
soluble and intact transporters) has already provided many important insights, still crystal 
structures present only snapshots.  The biochemical characterization of these and other ABC 
transporters will thus be essential to complement structural studies and to develop a full 
understanding of the mechanisms by which energy is transduced between the ABC domains 
and the transmembrane domains.  Characterization of the DrrAB drug export system can 
therefore provide a valuable understanding of the efflux systems, especially drug efflux 
systems. 
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The drrAB locus of S. peucetius has been subcloned and the proteins expressed in E. 
coli (2).  The expression of these two proteins confers doxorubicin resistance in this host, 
indicating that the complex is assembled properly (2).  Initial characterization of this system 
showed that DrrB is an integral membrane protein, and it contains eight transmembrane helices 
(6).  DrrA, a peripheral membrane protein, forms a complex with DrrB in the cell membrane, 
and it functions as the catalytic subunit (2).  Furthermore, DrrA and DrrB are biochemically 
dependent on each other for stability and function (4).  For example, DrrA binds ATP/GTP 
only if it is in a complex with DrrB in the membrane, and DrrB is unstable if DrrA is absent.  
While many of these factors make the study of this system quite challenging; at the same time, 
because of its separate subunit architecture and tight inter-subunit interactions, it makes for an 
ideal system to study NBD: NBD and NBD: TMD interactions.   
In a recent study conducted in this laboratory, we introduced several single cysteine 
substitutions in DrrB and then by using a cysteine to amine hetero-bifunctional cross-linker 
showed that DrrA interacts predominantly with the N-terminal cytoplasmic tail (residues 1-53) 
of DrrB (5).  Within this region of DrrB, we also identified a sequence with similarities to the 
EAA motif found in importers of the ABC family of proteins, thus leading to the proposal that 
the EAA or the EAA-like motif may be involved in forming a generalized interface between 
the ABC and the TMD of both uptake and export systems.  The goal of the present study was 
to characterize DrrA and to further our understanding of interactions between DrrA and DrrB.  
By using a combination of approaches, including point mutations, cysteine substitutions in the 
conserved domains of DrrA, and disulfide cross-linking analysis, we show here that the Q-loop 
region of DrrA plays an important role in dimerization of DrrA as well as in interactions with 
DrrB.  We provide evidence showing that DrrA can be trapped in the closed conformation by 
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placing a cysteine substitution in the Q-loop region, thus implying that in the closed 
conformation two Q-loops from opposing subunits are in close proximity with each other.  
Furthermore, we also show that the interaction of the Q-loop with the N-terminus of DrrB is 
involved in transmitting conformational changes between DrrA and DrrB.  Implications of 
these findings in the mechanism of the DrrAB complex are discussed, and a model depicting 
different conformations of DrrA and DrrB is presented.  While this manuscript was being 
completed, a similar study carried out with the maltose system was published.  This study 
supports and complements the conclusions of the present study by showing that in the closed 
state distance between the Q-loops of MalK is significantly reduced (22).   Findings of this 
study will also be discussed. 
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EXPERIMENTAL PROCEDURES 
Bacterial Strains and Plasmids:  The bacterial strains used in this study were E.coli TG1 (23), 
N43 (24), HMS174 (23), and XL1 Blue (23).  The plasmids used in this study included 
pDx101 (drrAB in pSU2718) and pDX121 (drrAB in pET28a). 
Media and Growth conditions:  The cells were grown in LB medium (25) at 37oC, unless 
mentioned otherwise.  Chloramphenicol was added to 20 µg/ml, and kanamycin was added to 
30 µg/ml, where needed. 
Site-directed mutagenesis of drrA:  Single and double cysteine variants of DrrA were 
constructed by site-directed mutagenesis using a strategene QuikChange multisite-directed 
mutagenesis kit (La Jolla, CA).  The strategy involved the use of complimentary primers that 
incorporated the change at the required position.  The templates used included pDx101 and 
pDx121, and the primers were designed as described earlier (5).  The single cysteine present in 
DrrB was first mutagenized to serine (C260S).  Cysteine substitution mutants were then 
created at amino acid positions 45, 89, 140, 174, 195 and 198 in DrrA.  These mutants were 
named A45CA(A)/C260S(B), Y89C(A)/C260S(B), Y140C(A)/C260S(B), 
S174C(A)/C260S(B), T195C(A)/C260S(B), and Y198C(A)/C260S(B).  For double-cysteine 
mutants, cysteine substitutions of DrrA were created in the DrrB S23C background.  Double 
substitutions were created at amino acid positions 89, 91,174,195 and 198 of DrrA.  These 
mutants were named Y89C(A)/S23C(B), S91C(A)/S23C(B), S174C(A)/S23C(B), 
T195C(A)/S23C(B) and Y198C(A)/S23C(B).  Conservative and non-conservative point 
mutations in certain residues in different domains of DrrA were also made.  These changes 
include G44S, G44A, K47E, K47R (Walker A), L160A, D164A, E165Q (Walker B), Q88E 
(Q-loop), and S141R and G143S (signature domain). 
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Doxorubicin Resistance Assay:  Doxorubicin resistance assays were carried out on M9 (23) 
plates supplemented with 0.25% casamino acids.  The plates were layered with 4 mL of top 
agar (0.8% agar in M9 medium) containing the desired concentration of doxorubicin.  Briefly, 
4 mL of top agar containing 0, 6, 8, or 10 µg/mL of doxorubicin (Sigma Chemicals) and 1 mM 
thiamine-HCl was poured on top of M9 plates.  The plates were covered with foil to prevent 
exposure to light.  N43, a doxorubicin-sensitive strain of E. coli, was transformed with the 
indicated plasmids.  Freshly transformed cells were grown for 8 hours in 3 mL of LB with the 
appropriate antibiotics.  1 µL of the 8 hour old N43 culture from above was streaked on plates 
containing doxorubicin.  N43 containing the plasmid pSU2718 was used as a negative control.  
The plates were then incubated at 37oC overnight, and growth was recorded after 24 hours of 
incubation. 
Nucleotide binding properties of DrrA mutants:  To study nucleotide binding, photolabeling of 
the various mutants of DrrA with [α-32 P] ATP was carried out (2, 4).  A 50 mL culture of 
E.coli TG1 cells containing the indicated plasmids was grown to mid-log phase and induced 
with 0.25 mM IPTG.  Growth was continued for an additional 3 hours at 37oC. The cells were 
spun down and resuspended in 1.5 ml QAE buffer (25 mM Tris.Cl, pH 8.0, 20% glycerol, 2 
mM EDTA) containing 1 mM DTT and lysed by a single passage through a French pressure 
cell at 20,000 psi.  The cell lysates were then centrifuged at 10,000 g for 15 minutes to remove 
unbroken cells.  The supernatant was centrifuged at 100,000 g for 1 hour to prepare membrane 
protein.  ATP binding assay was carried out in a 100 µl reaction volume containing 0.1 mg 
membrane protein, 25 mM Tris.Cl, pH 8.0, 20% glycerol, 2 mM EDTA, 10 µM ATP, 250 µM 
Mg2+,  35 µM dox, and 10 μCi [α-32 P] ATP.  The mixture was exposed to UV light at 254 nm 
for 30 minutes on ice.  Proteins were precipitated with 400 µl of 10% TCA on ice for 30 
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minutes.  Samples were spun down at 14,000 g for 15 minutes and the supernatant was 
resuspended in 20 µl 4X Laemmli sample buffer containing 5 µl of 1 M unbuffered Tris.  The 
samples were solubilized by heating at 55oC for 10 minutes and analyzed by SDS-PAGE using 
a 10% polyacrylamide gel, followed by autoradiography. 
Purification of wild-type and mutant DrrAB proteins: DrrAB proteins were purified using 
pDx121, which introduces his-tags at the N-terminus of DrrA and the C-terminus of DrrB.  
HMS174 cells containing the indicated plasmid were induced with IPTG, and membrane 
fractions were prepared, as described above.  DrrAB proteins were solubilized from the 
membrane and purified as a complex using Ni-NTA column.  The proteins were analyzed by 
SDS-PAGE using a 10% polyacrylamide gel, followed by Western blot analysis with anti-
DrrA or anti-DrrB antibodies.  Details of the method used for solubilization and purification of 
the DrrAB proteins are being reported elsewhere (unpublished data).  The yield of the DrrAB 
proteins was roughly 0.43 µg/ul.  
Homobifunctional (disulphide) and Heterobifunctional (cysteine to amine) Cross-Linking:  For 
homobifunctional cross-linking, a 100 µl reaction volume containing 250 µg of membrane 
protein in 0.1 M phosphate buffer, pH 7.4, was treated with thiol-specific reagents copper 
phenanthroline (CuPhe) (3 mM CuSO4/9 mM 1, 10 phenanthroline), DTME (Dithio-bis-
maleimidoethane) (1 mM) (Pierce chemicals), or MTS (3,6,9,12,15-Pentaoxaheptadecane-
1methanethiosulfonate) (0.2 mM) (Toronto Research Chemicals) for 30 minutes at room 
temperature.  For heterobifunctional cross-linking, a 100 µl reaction volume containing 250 µg 
of membrane protein in 0.1 M phosphate buffer, pH 7.4, was treated with GMBS (N-[γ-
maleimidobutyryloxy]succinimide ester) (1 mM) (Pierce Chemicals) for 1 hour at room 
temperature in a light-protected area.  The reactions were terminated by the addition of 25 µl 
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4X non-reducing Laemmli sample buffer.  The samples were mixed thoroughly and set aside 
for 5 minutes at room temperature.  A 25 µL portion (50 µg of membrane protein) of the 
reaction mixture was then analyzed by SDS-PAGE using a 10% polyacrylamide gel, followed 
by Western blot analysis using either anti-DrrA or anti-DrrB antibodies.  To study the effect of 
ATP and ATPγS on cross-linking, 35 µg purified wild-type or mutant DrrAB proteins were 
incubated with or without 10 µM ATPγS, 10 µM ATP, or 1 mM DTME for 30 minutes at 
room temperature.  Prior to incubation, purified proteins were reduced with 1 mM DTT and 
immediately passed through a 10K Nanosep centrifugal column (Pall Corporation) to remove 
DTT.  The reaction was terminated by the addition of 4X non-reducing Laemmli sample 
buffer.  15 µg protein was analyzed by SDS-PAGE, followed by western blot analysis. 
Determination of composition of the 78 kDa cross-linked species by SELDI:  DrrAB proteins 
containing a cysteine at position 89 in DrrA (labeled Y89C(A)/C260S(B)) were purified by 
using a Ni-NTA column.  The purified sample was subjected to disulphide cross-linking using 
DTME as described above.  The samples were analyzed by SDS PAGE using 10% 
polyacrylamide gel, followed by Coomassie Blue staining (23).  The band of interest was 
excised and subjected to in-gel digestion with 100 ng trypsin.  The mass of the trypsin- 
generated peptide fragments was determined by Surface Enhanced Laser Desorption/Ionization 
(SELDI) using the CIPHERGEN Protein Chip® Technology in the core facility of the 
Department of Biology at Georgia State University. 
Fourier resonance energy transfer (FRET):  In separate reactions, 5 mg of membrane protein 
prepared from A45C(A)/C260S(B) or Y140C(A)/C260S(B) was incubated with either 1mM 
NBD-Cl (7-chloro-4-nitrobenzo-2-oxa-1, 3-diazole) for 2 hours at 22oC or with 30 µM MIANS 
[2-(4’-maleimidylanilino) naphthalene-6-sulfonic acid] for 30 minutes at 22oC.  Unreacted 
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probes were quenched with 1 mM dithioerythritol (DTE), and the samples were passed through 
a desalting column (Zeba TM Desalt Spin column, Pierce). NBD or MIANS-labeled DrrAB 
proteins were solubilized and purified from the cell membrane, as described earlier.  For FRET 
analysis, 250 µL MIANS-labeled, purified A45C(A)/C260S(B) (approx. 100 µg of protein) 
proteins were mixed with 250 µL NBD-labeled, purified Y140C(A)/C260S(B) and incubated 
for 30 minutes at 22oC to obtain doubly-labeled MIANS-NBD-A45C/Y140C DrrAB dimers.  
As controls, MIANS-labeled A45C(A)/C260S(B) was mixed with NBD-labeled 
A45C(A)/C260S(B), and MIANS labeled Y140C(A)/C260S(B) was mixed with NBD labeled 
Y140C(A)/C260S(B) for 30 minutes to obtain doubly-labeled MIANS-NBD-A45C DrrAB and 
MIANS-NBD-Y140C DrrAB, respectively.  For clarity, the controls and the experimental set-
up are shown below in the form of a table. 
 
 
 
 
Fluorescence spectra were recorded on an Alphascan-2 spectrofluorimeter (Photon Technology 
International, London, Ontario, Canada).  The excitation and emission slits were set at 4 nm.  
The excitation wavelengths for MIANS and NBD fluorophores were 322 nm and 465 nm, 
respectively, while emission was monitored at 420 nm and 523 nm, respectively for individual 
probes.  However, for the energy transfer experiment (table above), samples were excited at 
322 nm (for MIANS) while emission was monitored between 350 nm and 600 nm to include 
both MIANS and NBD.  
 
 
MIANS A45C + NBD A45C Control 1 
MIANS Y140C+ NBD Y140C Control 2 
MIANS A45C + NBD Y140C Experiment 
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RESULTS 
Characterization of point mutations in DrrA:  DrrA, the ABC subunit of the DrrAB pump, 
contains several conserved domains, as shown in the alignment of the amino acid sequence of 
DrrA with 5 other importers and exporters belonging to the ABC family (Figure 1A).  The 
alignment was determined by ClustalW, and the secondary structure was analyzed by the PHD 
method of prediction.  The alignment highlights the conserved domains within the ATPase 
domain of each transporter and shows high sequence similarity between each of them.  These 
domains in DrrA have been diagrammatically represented in Figure 1B.  To study the effect of 
mutations within the conserved domains on function of the DrrAB transporter, both 
conservative and non-conservative changes in residues within each domain were made.  These 
include G44S, G44A, K47E and K47R in Walker A; L160A, D164A and E165Q in Walker B; 
Q88E in Q-loop; and S141R and G143S in the signature motif.  Protein expression analysis 
showed that mutations in the conserved domains caused varying degrees of reduction in the 
levels of DrrA and DrrB (Figure 2A, left panels) as compared to the wild-type.  Nucleotide 
binding properties of DrrA in each of these mutants was analyzed by [α-32P] ATP cross-
linking experiments.  These data are shown in Figure 2A, right panels.  As expected, Walker A 
mutations significantly reduced ATP binding to DrrA.  Interestingly, E165Q, a Walker B 
mutant, showed slightly higher levels of ATP binding as compared to the wild-type.  The 
conserved glutamate in the Walker B domain is known to be crucial for hydrolysis of ATP but 
not for ATP binding, thus the ATP binding phenotype observed for E165Q is consistent with 
that role.  (Preliminary studies conducted in this laboratory have shown that the Kd for ATP 
binding in both wild type and E165Q is in the range of 250-350 μM (data not shown)).  A non-
conservative mutation in the adjoining residue, D164A, showed drastic reduction in expression 
levels of DrrA and DrrB and thus prevented ATP binding.  Q88E mutation in the Q-loop 
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reduced ATP binding but did not completely abolish it, while the signature domain mutant, 
G143S, had no effect on binding of ATP. A non-conservative mutation, S141R, in the 
signature domain affected expression and completely abolished ATP binding.   
It was previously shown that [α-32P] ATP binding to wild type DrrA is competed by 
unlabeled ATP (2).  To determine if this is true for the [α-32P] ATP binding seen in the 
mutants, competition experiments using 10-fold and 50-fold higher concentration of unlabeled 
ATP were carried out using K47R, Q88E, E165Q, S141R.  Data in Figure S3 show that 10-fold 
higher concentration of unlabeled ATP is sufficient to completely prevent labeling with [α-
32P] ATP in all of the mutants tested.   Finally, ATP binding to DrrA is known to be 
stimulated by doxorubicin (2).  The ATP binding experiments shown in Figure 2A, 2B and 2C 
were carried out in the presence of doxorubicin, as indicated in Material and Methods.  The 
data in Fig. 2D, however, show [α-32P] ATP binding to a selected set of mutants both in the 
absence and presence of doxorubicin.  These data show that doxorubicin stimulates ATP 
binding to these mutants, as seen with the wild type protein.  E165Q, however, binds ATP well 
even in the absence of doxorubicin, indicating that this mutation traps the DrrA protein in the 
closed conformation.  The experiments shown in Figure 2A-2C were repeated three times.  .  
The intensities of the bands in both Western blots (left panels) and the autoradiograms (right 
panels) were determined by densitometric scanning using Quantity one analysis software 
(Biorad). The averages (from 3 or 4 experiments) of the ratio of ATP bound/protein 
concentration for selected mutants used for further experiments in this article were plotted in a 
histogram shown in Figure S2.  The error bars reflect standard deviations.  
To determine if mutations in DrrA have an effect on the overall function of the 
transporter, doxorubicin resistance assays were carried out.  The data show that while cells 
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containing wild-type DrrA and DrrB grow up to 10 µg/ml of doxorubicin (Table 1), the Q-loop 
mutant Q88E grows up to 6-8 µg/ml and all other mutants grow up to 4-6 µg/ml of 
doxorubicin.  Two non-conservative changes in the Q88 residue (Q88S and Q88N) were also 
made.  These two changes conferred greater sensitivity to doxorubicin as compared to Q88E.  
Some of these mutations described in Figure 2 were used in the following experiments 
described in this paper. 
Head-to- tail conformation of DrrA dimers:  To determine if DrrA undergoes head-to-tail 
dimerization, as reported for other ABC proteins (8, 16, 17, 20, 26-29), fourier resonance 
energy transfer (FRET) experiments were carried out.  In a head-to-tail dimer, the Walker A 
domain of one subunit is expected to interact with the signature domain of the other. To 
determine such a conformation, a single cysteine substitution was introduced within the 
Walker A (A45C(A)/C260S(B)) or the ABC signature motif (Y140C(A)/C260S(B)) of DrrA.  
The expression levels of DrrA and DrrB proteins in both of these mutants were unaffected 
(data not shown). The membrane fractions prepared from strains containing these mutations 
were then labeled with either MIANS or NBD-Cl.  Following incubation with either probe, the 
DrrAB proteins were immediately purified.  MIANS and NBD-Cl are fluorophores that 
become fluorescent only on binding to cysteine residues within a protein.  The fluorescent 
emission spectra were measured spectrofluorimetrically to determine whether binding of the 
probe to cysteines in DrrA took place.  Data in Figure 3A, panels A and B show that both 
A45C and Y140C could be labeled with either MIANS or NBD-Cl.  It has previously been 
shown that the fluorescence emission spectrum of MIANS overlaps fairly well with the 
absorbance spectrum of NBD-Cl (30).  Thus MIANS and NBD-Cl form a good donor-acceptor 
pair.  Once the labeling of DrrA with these probes was successfully achieved, we wanted to 
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determine if the energy transfer would occur between them.  If the DrrA dimer is a head-to-tail 
dimer, we would expect energy transfer between A45C-MIANS and Y140C-NBD-Cl.  Thus, 
in this experiment, excitation was carried out at 322 nm for MIANS, while emission was 
carried out between 350 nm and 600 nm to be able to observe fluorescence emission of both 
MIANS and NBD-Cl.  The data are shown in Figure 3A, panel E.  When excitation is carried 
out at 322 nm, MIANS-A45C protein shows an emission peak at 420 nm (Panel E, curve 1) as 
is also seen in panel A, (curve 1).  NBD-Y140C gives no signal under these conditions, (Panel 
E, curve 2), as expected.  When these proteins were mixed, excitation at 322 nm resulted in 
significant (about 90%) quenching of the MIANS emission peak (Panel E, curve 3).  This 
quenching is simultaneously accompanied by an emission peak at 530 nm (Panel E, curve 3) 
from NBD-Y140C.  These data show that fluorescence energy transfer occurred between 
MIANS bound to A45C and NBD-Cl bound to Y140C.  Control experiments, where A45C-
MIANS was mixed with A45C-NBD-Cl, or Y140C-MIANS was mixed with Y140C-NBD-Cl, 
are shown in Figure 3A, panels C and D, respectively.  When excitation was carried out at 
322nm, the fluorescence property of either probe in these situations remained unaltered (curve 
3), indicating that FRET did not occur between two probes in the Walker A domains or the 
signature domains.  These data indicate that the Walker A motif of one DrrA molecule lies in 
close proximity to the signature motif of another DrrA molecule in the DrrA dimer. The three 
dimensional model of DrrA dimers was built based on MalK dimer, the closest homologue 
whose structure had been published in the PDB (PDB accession code: 1Q12) (Figure 3B).The 
model shows a similar head-to-tail dimeric arrangement of the DrrA dimers compared to that 
of the MalK dimers.  
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Characterization of subunit interactions by use of disulphide cross-linkers:  The N-terminal 
cytoplasmic tail of DrrB, including residues 1- 53, was previously shown by GMBS-mediated 
(cysteine to amine) cross-linking experiments to be involved in interaction with DrrA (5).  To 
determine regions in DrrA that may be involved in interaction with the N-terminal region of 
DrrB, cysteine substitutions were made in DrrA.  Wild-type DrrA contains no cysteine, while 
wild-type DrrB contains one at position 260, which was modified to a serine (5).  Cysteine 
substitutions in DrrA were made in a plasmid already containing S23C substitution in DrrB, or 
in the cys-less DrrB background, unless indicated otherwise.  The residues chosen for cysteine 
substitutions in DrrA were selected so that they were positioned either within or at close 
proximity to conserved domains in DrrA, and that they would result in conservative changes.  
While ten double mutants were originally constructed, five mutations showed significantly 
reduced levels of DrrA and DrrB expression and thus were not used for further investigation.  
The remaining five double cysteine mutants (Y89C(A)/S23C(B), S91C(A)/S23C(B), 
S174C(A)/S23C(B), T195C(A)/S23C(B) and Y198C(A)/S23C(B)) were analyzed by cross-
linking with a 0 Å disulphide cross-linker, CuPhe.  Cross-linking between S23C in DrrB and a 
cysteine in DrrA is expected to result in a 65 kDa species.  The data in Figure 4 show, that in 
two cysteine mutants, namely Y89C(A)/S23C(B) and S91C(A)/S23C(B), both in the Q-loop 
region, a major cross-linked species migrating at about 78 kDa (marked as *) was produced 
instead.  This species was only seen in the blots probed with anti-DrrA antibody (Figure 4A), 
but was absent in the blots probed with anti-DrrB antibody (Figure 4B).  In addition, a minor 
65 kDa species (also marked as *) was also produced, which could be detected by both anti-
DrrA (Fig. 4A) and anti-DrrB (Fig. 4B) antisera, indicating that it is a complex of DrrA and 
DrrB.  In the blot shown in Fig. 4B (probed with anti-DrrB antibody), we also see DrrB dimers 
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in samples treated with CuPhe.  Since DrrB dimers are produced in all cysteine variants tested 
(not shown), this species results from non-specific association of DrrB monomers in the 
presence of a disulfide cross-linker.  Such non-specific association of cysteine variants of DrrA 
is clearly not seen (shown in Fig. 4A), thus we conclude that DrrB, being a membrane protein, 
is more prone to this kind of aggregation.   
When another disulfide cross-linker DTME was used, we found that once again the 
major cross-linked species with Y89C DrrA corresponded to 78 kDa in size (Fig. 5, lanes 3-4).  
To determine whether the 78 kDa cross-linked species was formed between two monomers of 
DrrA (Y89C(A)/Y89CDrrA) or between DrrA and DrrB (Y89C(A)/S23C(B)), two other 
variants of DrrB were tested.  One contained C260 as the only cysteine in DrrB 
(Y89C(A)/C260(B)) and the other contained no cysteine (Y89C(A)/C260S(B)).  DTME-
mediated disulphide cross-linking showed that the location of a cysteine in DrrB (whether 
S23C (Figure 5A, lanes 3-4) or C260 (Figure 5A, lanes 5-6)) made no difference to the Y89C-
mediated disulphide cross-linking.  Furthermore, the 78 kDa cross-linked species was formed 
even in the absence of a cysteine in DrrB (Figure 5A, lanes 7-8), suggesting that the cross-
linked species may be a homodimer of DrrA.   
To determine the exact composition of the 78 kDa cross-linked species and to verify 
that it represents DrrA dimer, the DrrAB proteins were purified from the single cysteine 
mutant (Y89C(A)/ C260S(B)) cloned in a pET vector (Figure 6).  The purified Y89C protein 
contained the 78 kDa species even without addition of the cross-linker (Figure 6, lane 9), 
indicating that the two cysteines are at very close proximity with one another and were 
therefore spontaneously oxidized to yield a disulphide cross-linked species.  The formation of 
the cross-linked species was further enhanced on addition of DTME (Figure 6, lane 10).  The 
  68 
gel slice containing the 78 kDa species was excised from the gel shown in Figure 6, lane 9, and 
subjected to SELDI analysis using the CIPHERGEN Protein Chip ® Technology, as described 
under Experimental Procedures.  Analysis of the peptide map of the 78 kDa species showed 
that 96.4% of the peptides generated by the 78 kDa species matched that of the DrrA protein.  
Therefore, all of the above data together suggest that the 78 kDa species is a multimer, most 
likely a dimer, of DrrA.   The DrrA monomer is 36.5 kDa in size, thus the dimer should 
migrate at 73 kDa on SDS-PAGE.  However, the cross-linked species migrates at about 78 
kDa.  This may be due to the specific conformation of the dimer resulting from cross-linking.  
To determine if formation of the 78 kDa DrrA dimeric species is DrrB-dependent, purified 
DrrA or DrrAB proteins were subjected to DTME cross-linking (Fig. 6B).  As reported earlier, 
both DrrA and DrrB proteins are dependent on each other for stability (4).  The expression of 
DrrA in the absence of DrrB is about 50-60% of the DrrAB-containing system, while the 
expression of DrrB protein is undetectable in the absence of DrrA (4).  The densitometric 
analysis of the monomeric and dimeric species seen in Fig. 6B show that while the yield of 
purified DrrA in DrrA-alone system is half of the DrrAB system, the yield of the cross-linked 
78 kDa species is almost 10-fold reduced, indicating that DrrB is required for efficient 
dimerization of DrrA.   
Effect of ATP and ATPγS on dimer formation:  To study the effect of nucleotide binding on 
DrrA homodimer formation, cysteine-less DrrAB and Y89C(A)/C260S(B) proteins were 
purified.  The purified proteins were incubated with ATP or the non- hydrolyzable analog 
ATPγS.  Since the purified Y89C DrrA protein spontaneously forms the 78 kDa species, the 
samples were first reduced with DTT to break up the disulphide bonds (Figure 7A, lane 1).  On 
addition of DTME (Figure 7A, lane 4), or ATPγS (Figure 7A, lane 3) to this reduced protein, 
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the 78 kDa species was again seen.  Addition of ATP to the Y89C protein (Fig. 7A, lane 2) or 
ATPγS to the cysteine-less mutant did not induce dimerization (Figure 7A, Lane 7).  To 
determine the role of the nucleotide binding domain in Y89C-mediated dimerization, a K47R 
mutation in the Walker A domain was constructed in the existing Y89C(A)/C260S(B) mutant.  
K47R mutation completely abolished ATP binding to DrrA (Figure 3, panel A).  The resulting 
mutant protein (Y89C, K47R(A)/C260S(B)) was purified and cross-linked with the disulphide 
cross-linker DTME (Figure 7B).  The DrrA protein in this mutant failed to dimerize in the 
presence of DTME even though it contained the Y89C mutation (Figure 7B, lanes 5-6).  
Further characterization was done by using E165Q, a mutation in the Walker B domain.  Since 
E165Q binds ATP very well (Figure 3B, right panel), this mutation was introduced in the 
existing Y89C(A)/C260S(B) mutant.  This protein was able to form disulphide cross-linked 
species in the presence of DTME (Figure 7C, lane 8).  Furthermore, this protein also showed 
significant dimerization on addition of either ATP or ATPγS, even without addition of DTME 
(Figure 7C, lanes 5-7).  E165Q alone, in the absence of Y89C mutation, did not show 
dimerization in the presence of DTME, ATP or ATPγS (Figure 7C, lanes 1-4).  Together, the 
data from Figures 7B and 7C suggest that an intact ATP binding Walker A domain is required 
for the formation of DrrA dimers and that the Y89C dimers can be held together either by use 
of the disulfide cross-linker or by binding of ATPγS to the dimer interface. The data shown in 
this Figure were quantitated, as described for Figure. 2.  The averages of the ratio of cross-
linked dimer/monomeric DrrA protein were plotted in a histogram shown in Figure S4.  The 
error bars represent standard deviation.  
Effect of DrrB on conformation of DrrA:  As shown in the previous experiments, disulphide 
cross-linking using DrrAB containing one cysteine in DrrA (Y89C(A)/C260S(B)), or two 
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cysteines - one each in DrrA and DrrB (Y89C(A)/S23C(B)), results predominantly in the 78 
kDa DrrA homo-dimeric species, indicating that Y89C is in close contact with Y89C from 
another subunit of DrrA.  A minor 65 kDa species, consisting of DrrA and DrrB, is also seen 
when S23C in DrrB is simultaneously present.  To further characterize DrrA-DrrB interaction, 
a cysteine to amine cross-linker GMBS was used.  GMBS cross-linking of six different 
cysteine substitutions in DrrA with DrrB was analyzed.  These included A45C(A)/C260S(B), 
Y89C(A)/C260S(B), Y140C(A)/C260S(B), S174C(A)//C260S(B), T195C(A)/C260S(B) and 
Y198C(A)/C260S.  Of these, only Y89C and Y140C, both in the helical domain of DrrA, 
showed cross-linking with GMBS.  Moreover, they produced identical cross-linking patterns.  
Only the data obtained with GMBS cross-linking of Y89CDrrA are shown in Fig. 8A.  In this 
experiment, (A)/S23C(B) served as a control.  GMBS cross-linking of S23C with an amine in 
DrrA produces a major 65 kDa DrrA + DrrB species (Figure 8A and 8B, lanes 1 and 2), as was 
also reported earlier (5).  Y89C(A)/C260S(B) showed a different cross-linking pattern, 
however (Figure 8A, lanes 3-4).  Three cross-linked species were seen: a minor 65 kDa 
species, and two major species of 78 kDa and around 100 kDa. The 65 kDa species 
corresponds to a heterodimer of A + B and is detected by both anti-DrrA (Fig. 8A, lane 4) and 
anti-DrrB antisera (Fig. 8B, lane 4), while the 78 kDa species is a homodimer of DrrA and is 
detected only by anti-DrrA antibodies (Fig. 8A, lane 4) and not by anti-DrrB serum (Fig. 8B, 
lane 4).  The third 100 kDa species is again detected by anti-DrrA antibodies (Fig. 8A, lane 4), 
but not by anti-DrrB antibodies (Fig. 8B, lane 4).  The significance of the 100 kDa species is 
not clear at this moment.  Since it is not detected by anti-DrrB, it is likely that it represents a 
different conformation of the Y89C DrrA homodimer that has been doubly cross-linked 
through GMBS-mediated cysteine-amine cross-links, thus resulting in a different mobility.  
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The composition of this species will be analyzed further in the future studies.  However, the 
most important conclusion that can be drawn from the GMBS cross-linking experiment shown 
in Figure 8A, lanes 3-4 (as is also seen with disulfide cross-linkers) is that once a cysteine is 
placed in the Q-loop/helical domain of DrrA, the predominant interaction is between DrrA 
monomers.  Since a minor 65 kDa DrrA-DrrB species is also produced, it indicates that the 
same region of DrrA is also involved in interaction with DrrB.  GMBS cross-linking 
experiments also provided another interesting insight.  It was noted that the presence of S23C 
(DrrB) simultaneously with Y89C (DrrA) interfered with the formation of the DrrA 
homodimers as well as the 100 kDa species (Figure 8A, lane 6), suggesting that the 
introduction of S23C in DrrB affects Y89C mediated A-A interaction.  Furthermore, these data 
indicate that the three situations, S23C, Y89C, and Y89C-S23C represent three different 
conformations of DrrA and DrrB.   
The effect of S23C in DrrB on Y89C in DrrA was analyzed further by use of the 
disulphide cross-linkers. In Figure 9A, results obtained with three cross-linkers of different arm 
lengths are compared.  These include CuPhe (0 Å), DTME (13.3 Å) and MTS (24.0 Å).  All 
three cross-linkers showed the formation of the 78 kDa cross-linked species with equal 
efficiency when Y89C (A)/C260S (B) is used (Figure 9A, lanes 1-4).  Interestingly, however, 
when S23C is also present, MTS-mediated cross-linking between Y89C-Y89C is prevented 
(lane 9), even though cross-linking by CuPhe (lane 7) and DTME (lane 8) was unaffected.  
These data indicate that S23C did not prevent DrrA-DrrA interaction but somehow altered it so 
that it is not picked up by the long arm-length cross-linker MTS.  In the MTS-treated samples, 
the only species seen is the 65 kDa (A+B) species (Figs. 9 A and 9B, lane 9), as is also seen in 
the CuPhe (lane 7), and to a lesser extent in the DTME-treated, samples.  (A smaller species of 
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about 55 kDa, picked up by anti-DrrA antibodies in the CuPhe sample, has not been 
characterized further in this study.)  The data shown in this Figure were quantitated, as 
described earlier for Figure. 2.  The averages (cross-linked dimer/monomeric DrrA protein) 
were plotted in a histogram shown in Figure S5.  The error bars reflect standard deviation.   
To determine if presence of any other cysteine in DrrB could have a similar inhibitory 
effect on Y89C-Y89C cross-linking, Y89C(A)/C260(B) was tested.  Data in Figure 9C (lanes 
1-4) show that MTS-mediated Y89C-Y89C cross-linking was not prevented by C260.  Thus, 
this effect was specific to S23C (N-terminal tail) of DrrB.  Furthermore, if S23C in DrrB is 
replaced by S23A, once again MTS-mediated Y89C-Y89C cross-linking occurs normally 
(lanes 5-8), indicating that a cysteine residue at position 23 in DrrB is required for this effect. 
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DISCUSSION 
A major unresolved question that intrigues investigators in the field of ABC transporters is the 
mechanism by which their nucleotide binding domains interact with the membrane domains, a 
step essential for transduction of energy to bring about import or export.  In this laboratory, our 
focus is an ABC drug transporter, DrrAB, which carries out efflux of the anticancer drugs 
doxorubicin and daunorubicin.  In previous studies conducted in this laboratory, we found that 
the NBD and the TMD of the DrrAB system, even though present on separate subunits, are 
tightly coupled for their function and stability, implying specific interaction between the 
subunits (4).  Recently our efforts have focused on understanding the molecular basis of 
interaction between DrrA and DrrB (5).  In the present study, cysteine substitutions were made 
near the conserved domains of DrrA to understand interactions between subunits by using 
cysteine-cysteine or cysteine-amine cross-linking approaches.  We show here that the Q-loop 
region of DrrA plays an important role in dimerization of the nucleotide binding domains, and 
it is also involved in mediating interactions between the NBD and the transmembrane subunit 
DrrB.  Furthermore, we show that this interaction plays a role in communication of 
conformational changes between DrrA and DrrB.  The critical role played by the Q-loop in the 
function of ABC transporters has been recognized before in structural studies carried out with 
MalK and BtuCD, among others (17, 20).  Similarly, biochemical studies carried out 
previously with the maltose and the Bmr systems have also pointed to the importance of the Q-
loop region (22, 31-35).  The results obtained in the present study not only strengthen previous 
observations but also extend them further 1) by showing that the Q-loop plays a role in 
producing the closed conformation of DrrA and 2) by providing evidence for communication 
between the closed conformation of DrrA and the transmembrane domain via the N-terminal 
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region of DrrB.  We present a model in Fig. 10, which attempts to interpret and summarize the 
data obtained in this study and presents this information in the context of information already 
available in literature on other ABC proteins.   
Previous studies from this laboratory have shown that in the resting state of the 
complex, DrrA is in contact with DrrB.  We showed that if membranes containing the wild 
type DrrA and DrrB proteins are treated with DTSSP, a general amine-to-amine cross-linker, 
only a heterodimeric species consisting of DrrA and DrrB is seen (4), implying that in the 
resting state DrrA is predominantly in contact with DrrB and not another monomer of DrrA.  
This state is represented as A-B in the model shown in Figure 10.  The resting state complex of 
DrrA and DrrB could also be identified in GMBS (a cysteine to amine cross-linker) cross-
linking experiments where it was shown that residues in the N-terminal cytoplasmic tail of 
DrrB (residues 1-53) are involved in interaction with DrrA (5).  In the present study, we show 
that a cysteine substitution in the Q-loop of DrrA produces a conformational switch from A-B 
conformation to the A-A homodimeric state.  An important step in the catalytic mechanism of 
ABC transporters is the dimerization of their nucleotide binding domains (8, 14, 16, 17, 20), 
however the dimeric state is transient (since hydrolysis of ATP immediately returns the protein 
to the open conformation) and thus is difficult to identify in solution or in the crystalline state .  
In some proteins (for example, MJ0796), mutation of the catalytic glutamate in the Walker B 
domain was shown to enhance stability of the dimer and was essential for crystallization of the 
protein in the dimeric state (36).  In this study, we found that the Y89C or S91C substitution in 
the Q-loop traps DrrA in the dimeric conformation, which could be identified by use of a zero 
arm-length disulfide cross-linker, copper phenanthroline.  Since cysteine substitutions in other 
regions of DrrA did not result in the same effect, our data suggest that the Q-loop region is 
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present at the interface of two monomers and is actively involved in dimerization of DrrA.  
Further, we propose that the Y89C-induced conformation of DrrA resembles the closed state, 
which normally results from binding of ATP to the ABC proteins (8, 14, 16, 17, 20).  We 
found that Y89C-mediated cross-linking by DTME was independent of ATP binding (Fig. 5B, 
lanes 2 and 3) (presumably because most of the protein was already in the dimeric state); 
nevertheless, an intact ATP binding (Walker A) domain was required for achieving this 
conformation.  Furthermore, on the addition of a non-hydrolysable ATP analog, ATPγS, a 
stable Y89C DrrA dimer was produced even in the absence of the cross-linker, suggesting that 
in this situation the ATP analog serves to hold the Y89C dimer together.  If E165Q, a mutation 
in the Walker B domain that prevents hydrolysis of ATP, is simultaneously present along with 
Y89C, then either ATP or ATPγS could substitute for the disulfide cross-linker.  Based on 
these observations, we can conclude that the Y89C-Y89C contact is sensitive to binding of 
ATP/ ATPγS so that the Y89C dimer can be stabilized either by the disulfide cross-linker 
acting directly on the Q-loop or by binding of ATPγS to the interface of the dimer.  These data 
imply that the Y89C dimeric conformation indeed resembles the closed state.  Thus the 
phenomenon noted here is physiologically significant and is likely to be part of a transport 
cycle.  Information gleaned from the MalK structure also shows that the Q-loops move much 
closer together in the closed state and that the distance between Q-loops from opposing 
subunits changes from 52.5 Å (open) to 27.2 Å (closed) state (17).  The most recent 
biochemical study from Schneider’s group on the maltose system also strengthens the data and 
interpretations presented in this study (22).  They show that distances between Q-loops of 
MalK are significantly reduced during transition from the open to the closed state and, 
furthermore, that MalK can be fixed in the closed state by a mutation of the catalytic glutamate 
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(E159Q) or in the open state by a mutation in the signature motif (Q140K) of MalK.  Our 
studies show similar, though not identical, results.  Even though we interpret our results 
slightly differently, both studies are consistent with the model proposed for the open and 
closed conformations of MalK (22).  The biggest difference between the two studies is that we 
are proposing that Y89C DrrA protein is already trapped in the closed, though flexible, 
conformation (the maximum distance between Q-loops being in the viccinity of 24 Å, which is 
close to the distance reported for the closed conformation of MalK).  We base this on the 
observation that most of the Y89C protein forms dimers in the presence of CuPhe or a 
cysteine-to-amine cross-linker GMBS.  Binding of ATP to Y89C protein has no further effect 
on cross-linking.  Furthermore, in the resting (open) state, we see only A-B and no A-A 
conformation.  As soon as Y89C mutation is introduced, however, we see mostly A-A (and 
very little A-B) implying a switch in the conformation.  The idea that Y89C-Y89C contact is 
flexible comes from the observation that several cross-linkers of different arm-lengths can 
cross-link Y89C with equal efficiency.  This is discussed again later. 
Another aspect of the work described in this study involves interaction between the Q-
loop of DrrA and the N-terminal cytoplasmic tail of DrrB.  When S23C, a cysteine substitution 
of the S23 residue in the N-terminus of DrrB, is simultaneously present along with Y89C in 
DrrA, a species corresponding to the heterodimer of DrrA and DrrB (65 kDa) is also observed, 
although the major interaction is between two DrrA monomers.  Since Y89C represents the 
dimeric state of DrrA, the S23C-Y89C contact appears to be specific to the closed state and is 
represented as A-B* in Figure 10.  (We believe that the A-B* conformation is different from 
the A-B conformation described earlier, even though both involve the N-terminal tail region of 
DrrB.  This question will be resolved in the future studies).  What might be the significance of 
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the contacts between the S23 region (N- terminal cytoplasmic tail) in DrrB and the Q-loop of 
DrrA?  According to the prevalent models, the flexible nature of the Q-loop allows transition 
of the NBDs from the open to the closed state and at the same time, it allows it to act as a relay 
of conformational changes between the nucleotide binding domain and the transmembrane 
domain (37).  Supporting these ideas is the crystal structure of the intact transporter BtuCD, 
which shows that the Q-loop is present in a cleft on the surface of BtuD where it forms 
extensive contacts with the L-loop (analogous to the EAA loop) of BtuC (20).  Similarly, when 
the ATP-bound MalK structure was aligned with BtuC (TMD), it showed that the Q-loop of 
MalK is positioned to mediate tight binding to the L-loop of BtuC and it also reaches in 
towards the γ-phosphate of ATP in the closed conformation of MalK (17).   
Based on our own data presented here, we propose that the interaction between the S23 
region of DrrB and the Q-loop of DrrA is involved in communication of conformational 
changes between DrrA and DrrB.  The direct evidence of communication comes from the 
interesting observation that substituting S23 residue with S23C produces a significant effect on 
the behavior of Y89C in DrrA.  This effect becomes evident only when different arm-length 
disulfide cross-linkers are employed.  As mentioned in the results, DrrA (Y89C) can be cross-
linked with linkers varying in length from 0 (CuPhe) to 24 Å (MTS).  Interestingly, when 
S23C is simultaneously present in DrrB, the results are strikingly different:  copper and DTME 
(13.3 Å) can still cross-link DrrA and produce DrrA homodimers very well, but MTS is now 
not able to do so.  These data indicate that placing a cysteine in this region of DrrB produces a 
conformational change in the helical domain of DrrA.  How S23C achieves this effect is not 
completely clear at this time.  However, it seems reasonable to suggest that it produces a more 
rigid conformation of DrrA so that Y89C can still be cross-linked with zero or short arm length 
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cross-linkers but not with the long arm length linker MTS.  This leads us to propose that the 
two Y89C residues (or the Q-loops) from opposing monomers are in flexible contact until a 
conformational change in DrrB (produced by S23C substitution here) produces a change in 
DrrA which fixes it in one position.  Since only a cysteine substitution of S23 results in this 
effect, it might indicate affinity between the two cysteines, S23C and Y89C; however, instead 
of resulting in opening of the NBD dimer, the result of this interaction seems to be to fix the 
distance between DrrA monomers at less than 13 Å.  It seems that the overall effect of this 
conformation of DrrB is to facilitate the closed conformation of DrrA.  This observation is 
consistent with earlier findings, namely that the isolated ABC domains do not form stable 
homodimers even in the presence of Mg-ATP or non-hydrolyzable analogs, indicating that 
interaction with the TM domains is required for stable association (14).  Previous studies from 
this laboratory have also shown that DrrA is in an active conformation to bind ATP only when 
it is in complex with DrrB (4), further strengthening the idea that DrrB facilitates the closed 
conformation of DrrA.  Since S23C lies in the region of interaction between DrrA and DrrB, 
the effect seen in the present study is likely to be physiologically significant and thus may 
provide clues to the path of transmission of conformational changes from DrrB to DrrA.  One 
situation where events in DrrB will be transmitted to DrrA is substrate binding to DrrB.  This 
kind of signaling has been proposed to occur in the maltose system where substrate binding to 
the TMDs is believed to be signaled to the NBDs, resulting in their closing (38).  We have 
already shown that doxorubicin binding to DrrB produces a significant enhancement of ATP 
binding to DrrA (4).  It can thus be speculated that doxorubicin binding to DrrB produces a 
conformational change in the N-terminal tail of DrrB which is then transmitted to the helical 
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domain of DrrA.  Is it possible then, that the S23C substitution in the N-terminal tail of DrrB 
mimics the effect of substrate binding to DrrB?   
In this study the role of the Q-loop region in formation of the closed conformation of 
the nucleotide binding domain has been clearly elucidated.  Furthermore, the long-range effects 
of conformational changes in DrrB on DrrA are very intriguing and could provide important 
insights into the mechanism by which DrrA and DrrB communicate. In our future studies, we 
would like to further understand how DrrB influences DrrA and how the Q-loop region is 
involved in communication between the NBD and the TMD. 
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TABLE 1:  Doxorubicin Resistance of E.coli N43 Cells expressing different mutations in 
DrrA and wild type DrrB.  N43 cells containing indicated plasmids were plated on M9 plates 
containing different concentrations of doxorubicin.  The plates were incubated at 37 oC. 
Growth was scored after 24 hours of incubation.  Legend: +++, very good growth; ++, good 
growth; +, some growth; -, no growth 
Dox conc, µg/mL Domain of DrrA Mutation 
0 6 8 10 
(wild type) C260 +++ +++ +++ ++ 
cys-less C260S +++ +++ +++ ++ 
Walker A domain A45C +++ +++ + + 
Walker A domain G44A +++ +/- - - 
Walker A domain K47R +++ - - - 
Walker B domain L160A +++ - - - 
Walker B domain D164N +++ - - - 
Walker B domain E165Q +++ - - - 
Q-loop domain Y89C +++ +++ ++ + 
Q-loop domain S91C +++ +++ ++ + 
Q-loop domain Q88E +++ ++ + - 
Q-loop domain Q88S +++ - - - 
Q-loop domain Q88N +++ + - - 
Signature domain Y140C +++ +++ +/- +/- 
Signature motif S141R +++ + - - 
Signature motif G143S +++ + - - 
N-ter tail (DrrB) S23C +++ ++ ++ ++ 
Double mutant Y89C/S23C +++ +++ ++ ++ 
Double mutant S91C/S23C +++ ++ ++ ++ 
Vector only pSU2718 +++ +/- - - 
 aLegend: +++, very good growth;  ++, good growth;  +, some growth;  -, 
no growth. 
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FIGURES 
 
 
 
 
 
 
 
 
FIGURE 1:  A, Nucleotide Binding Domains of different ABC transporters:  Alignment of 
DrrA, HisP, MalK, MJO796, Sav1866 and BtuD was generated by ClustalW 
(http://www.ebi.ac.uk/clustalw/).  Secondary structure was predicted by the PHD tool obtained 
on the ExPASy server (us.expasy.org/).  Conserved domains mentioned in the text, namely 
Walker A, Walker B, signature motif, and Q-loop, have been highlighted in grey.  Other 
highlighted domains include the D-loop and the switch region. 
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B A schematic representation of the conserved domains in DrrA:  The location, length and 
consensus sequence of Walker A, Walker B, signature motif, helical domain, and the switch 
region are shown. 
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FIGURE 2:  Effect of various mutations in DrrA on expression levels of DrrA and DrrB 
and on ATP binding:  E. coli cells containing the indicated plasmids were induced with IPTG.  
The cells were lysed by French press, followed by ultracentrifugation at 100,000g for 1hr to 
prepare membrane fractions.  25 µg of membrane protein was analyzed by SDS-PAGE on 10% 
gels, followed by Western Blot analysis using anti-DrrA (upper panel) or anti-DrrB (lower 
panel) antibodies.  UV-catalyzed adduct formation between DrrA proteins and [α-32P] ATP 
was performed as described under “Experimental Procedures”.  The proteins were resolved by 
SDS-PAGE on 10% gels, followed by autoradiography.  Panels A-C, Left panels: Western 
blots; Right panels: [α-32P] ATP binding. A: Walker A mutants, B: Walker B mutants, C: Q-
loop and signature motif mutants.  Panel D: [α-32P] ATP binding in the presence or absence of 
doxorubicin.  Experimental conditions were the same as described for panels A-C.  The 
samples marked “+” contained 34 μM doxorubicin, while the samples marked “–“ contained 
no doxorubicin.  The experiments shown in Figure 2 were repeated three times.  The data 
obtained with key mutants (those used in this work) were quantitated and plotted as histograms 
provided in the Supplementary information.   
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FIGURE 3A:  Fourier Resonance Energy Transfer (FRET) analysis to determine the 
conformation of DrrA dimers:  The membrane fractions prepared from cells containing 
A45C(A)/C260S(B) or Y140C(A)/C260S(B) were labeled with either MIANS or NBD-Cl.  
The labelled DrrAB proteins were purified as described in “Experimental Procedures”.  A and 
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B: Fluorescence spectra for individual proteins labeled with MIANS (excitation at 322 nm; 
emission at 420 nm) or NBD (excitation at 465 nm; emission at 523 nm).  C: In separate 
reactions, A45C(A)/C260S(B) was labeled with either MIANS or NBD.  The individually 
labeled proteins were then mixed.  Excitation was carried out at 322 nm for MIANS and 
emission was monitored between 350nm and 600nm.  D: In separate reactions, 
Y140C(A)/C260S(B) was labeled with either MIANS or NBD.  The individually labeled 
proteins were then mixed.  Excitation was carried out at 322 nm for MIANS and emission was 
monitored between 350nm and 600nm.  E: A45C(A)/C260S(B) labeled with MIANS was 
mixed with Y140C(A)/C260S(B) labeled with NBD-Cl.  These two labeled proteins were 
mixed.  Excitation was carried out at 322 nm for MIANS and emission was monitored between 
350nm and 600nm. 
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FIGURE 3B: Close-up view of the three-dimensional model of MalK dimer (A) and DrrA 
dimer (B): The three dimensional model of DrrA dimer built based on MalK dimer, the closest 
homologue whose structure had been published in the PDB (PDB accession code: 1Q12). The 
3D model was built using Geno3D, a comparative molecular modeling program for proteins. The 
ATP co-ordinates were taken from the MalK model. The visualization of the models was 
performed using 3D Mol Viewer. Highlighted in the models are 1) the putative distances 
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between the Gln residues of the Q-loop (Q79-Q79 of MalK and Q88-Q88 of DrrA) 2) the 
putative distances between the Gln residue and ATP molecule. Also highlighted are the H190 
(Malk) and Q197 (DrrA) residues of the switch region of the respective proteins. 
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FIGURE 4:  Copper phenanthroline-mediated disulphide cross-linking of DrrAB 
proteins:  The cell membrane fractions were prepared and subjected to disulphide cross-
linking using copper phenanthroline, as described under “Experimental Procedures”.  The 
reaction was terminated by the addition of 25 µL 4X non-reducing Laemmli sample buffer.  50 
µg of protein was resolved by SDS-PAGE using 10% gels followed by Western blot using 
anti-DrrA or anti-DrrB antibodies.  Lanes 1 and 2, Wild-type DrrAB; lanes 3 and 4, cysteine-
less DrrAB; lanes 5 and 6, (A)/S23C(B); lanes 7 and 8, Y89C(A)/S23C(B); lanes 9 and 10, 
S91C(A)/S23C(B); lanes 11 and 12, S174C(A)/S23C(B); lanes 13 and 14, T195C(A)/S23C(B); 
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and lanes 15 and 16, Y198C(A)/S23C(B).  Panel A, anti-DrrA; Panel B, anti-DrrB. The 
“minus” and “plus” at the bottom of the lanes indicate the absence and presence of the cross-
linker in the reaction, respectively.  The migration of the protein standards is shown on the left.  
The location of the 78kDa as well as the 65 kDa cross-linked species is marked as “*”.  A much 
larger species seen in Y198C (A)/S23C (B) in both absence and presence of the cross-linker 
(**) was not characterized further in this study. 
  96 
 
 
 
 
 
FIGURE 5:  DTME-mediated disulphide cross-linking of Y89C (DrrA) and variants of 
DrrB:  The conditions used for disulphide cross-linking were as described under legend to 
Figure 4.  The reaction was terminated by the addition of 4X non-reducing Laemmli sample 
buffer.  50 µg of protein was resolved by SDS-PAGE followed by Western blot using anti-
DrrA antibodies.  Lanes 1 and 2, cysteine-less DrrAB; lanes 3 and 4, Y89C(A)/S23C(B); lanes 
5 and 6, Y89C(A)/C260(B); lanes 7 and 8, Y89C(A)/C260S(B).  The “minus” and “plus” at the 
bottom of the lanes indicate the absence and presence of the cross-linker in the reaction, 
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respectively.  The migration of the protein standards is shown on the left.  The location of the 
78 kDa cross-linked species is marked as “*”. 
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FIGURE 6:  Purification of the DrrAB proteins and cross-linking by DTME:  Membrane 
fraction was prepared as described in legend to Figure 3 and DrrAB purified as described in 
“Experimental Procedures”.  Samples were resolved by 10% SDS-PAGE followed by Western 
blot using anti-DrrA antibodies.  Panel A: Lanes 1-5, cysteine-less DrrAB; lanes 6-10, 
Y89C(A)/C260S(B). Lanes 1 and 2, membrane proteins (MP); lane 3, solubilized protein (SP); 
and lanes 4 and 5, purified protein (PP).  Panel B: Lanes 1 and 2, Y89C(A)/C260S(B); lanes 3 
and 4, Y89C(A) alone. 
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The “minus” and “plus” at the bottom of the lanes indicate the absence and presence of the 
DTME cross-linker in the reaction, respectively.  The migration of the protein standards is 
shown on the left.  The location of the 78 kDa cross-linked species is marked as “*”. 
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FIGURE 7:  Effect of ATP and ATPγS on DrrA homodimer formation:  DrrAB proteins 
were purified as described under “Experimental Procedures”.  Samples were reduced with 
1mM DTT and passed through a 10K Nanosep centrifugal column.  The reduced samples were 
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incubated with ATP, ATPγS, or DTME cross-linker.  The reactions were terminated by the 
addition of 4X non-reducing Laemmli sample buffer.  15µg of each sample was analyzed by 
SDS-PAGE, followed by Western blot using anti-DrrA antibodies.  Panel A:  Lanes 1-4, 
Y89C(A)/C260S(B); lanes 5-8, Cysteine-less DrrAB.  Panel B:  Lanes 1 and 2, Cysteine-less 
DrrAB; lanes 3 and 4, Y89C(A)/C260S(B); lanes 5 and 6, Y89C, K47R(A)/C260S(B).  Panel 
C:  Lanes 1-4, E165Q(A)/C260S(B); lanes 5-8, Y89C, E165Q(A)/C260S(B).  The “minus” and 
“plus” at the bottom of the lanes indicate the absence and presence of ATP, ATPγS, or the 
DTME cross-linker in the reaction.  The migration of the protein standards is shown on the left.  
The location of the 78kDa cross-linked species is marked.  
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FIGURE 8: GMBS- mediated heterobifunctional cross-linking:  The cell membrane 
fractions were prepared, as described earlier.  Cross-linking was carried out as described under 
“Experimental Procedures”.  The reaction was terminated by the addition of 4X non-reducing 
Laemmli sample buffer.  50 µg of protein was resolved by SDS-PAGE, followed by Western 
blot using anti-DrrA or anti-DrrB antibodies.  Lanes 1 and 2, (A)/S23C(B); lanes 3 and 4, 
Y89C(A)/C260S(B); lanes 5 and 6, Y89C(A)/S23C(B).  Panel A, anti-DrrA; Panel B, anti-
DrrB.  The location of the cross-linked species is marked as “A + B”, “A + A”, and “A + A?” 
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FIGURE 9: Use of disulphide cross-linkers of different arm-lengths:  The protocols for 
membrane preparation and cross-linking analyses were same as described under legend to Fig. 
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3.  Three cross-linkers of different am-lengths were used.  These include 3 mM/9 mM CuPhe 
(0 Å), 1 mM DTME (13.3 Å), or 0.2 mM MTS (24.0 Å). Lanes 1-4, Y89C(A)/C260S(B); lanes 
5-9, Y89C(A)/S23C(B). Cross-linked samples were probed with anti-DrrA or anti-DrrB 
antibodies.  Panel A, anti-DrrA; Panel B, anti-DrrB.  Panel C: Lanes 1- 4, Y89C(A)/C260(B); 
and lanes 5-8, Y89C(A)/S23A, C260(B).  Cross-linked samples were probed with anti-DrrA 
antibodies.   
The “minus” and “plus” at the bottom of the lanes indicate the absence and presence of the 
cross-linker in the reaction, respectively.  The migration of the protein standards is shown on 
the left.   
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FIGURE 10:  A model showing different conformations of DrrA and DrrB involved in the 
mechanism of doxorubicin efflux by the DrrAB pump.  The model depicted here is based on 
analyses of Y89C and S23C substitutions in DrrA and DrrB, respectively.  The resting-state 
complex of DrrA and DrrB (Confo. I, represented as A-B) is shown on the left. This state was 
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previously identified through DTSSP and GMBS cross-linking experiments (4,5).  In this state, 
the DrrA monomers are away from each other, and the primary interaction occurs between the 
N-terminal cytoplasmic tail of DrrB and an unidentified region of DrrA (5).  The helical domains 
of DrrA monomers are shown either facing towards each other (IA) (as seen in ref. 22), or away 
from each other (IB) (as proposed in ref. 32).  Y89C substitution in DrrA changes the 
conformation to that resembling the closed conformation (Confo. IIA), as seen in disulfide cross-
linking experiments presented in this study.  In this conformation, the two Q-loops are close 
together (A-A), and they also form transient contacts with the N-terminal tail of DrrB 
(represented as A-B*).  The Y89C-Y89C contact in this conformation is flexible (shown as a 
moving arrow), however simultaneous presence of S23C in DrrB produces a more rigid, closed 
conformation (Confo. IIB).  This conformation resembles the conformation resulting from 
binding of doxorubicin to the wild type DrrB, and it is competent to bind ATP.  This is consistent 
with previous studies conducted in this laboratory which show that ATP binding to DrrA occurs 
only when DrrA is in a complex with DrrB (4), and, furthermore, ATP binding to DrrA is 
stimulated by doxorubicin binding (2,4).  Binding of ATP to this conformation then serves as the 
power stroke (Confo. IIC) for efflux of doxorubicin.  Hydrolysis of ATP subsequently returns the 
pump to the resting state. 
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SUPPLEMENTARY DATA 
 
 
 
 
 
 
 
 
 
FIGURE S1: Alanine scanning mutagenesis of DrrA: To determine the domains in DrrA that 
have an effect on the expression and overall function of the DrrAB proteins, alanine substitutions 
were made all along the length of the DrrA proteins approximately 15 residues apart. The 
proteins were resolved by SDS-PAGE on 10% gels, followed by autoradiography. 
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FIGURE S2: Quantitation of the ratio of ATP bound/protein concentration of point 
mutations in DrrA: The data shown in Figure 2 were quantitated. The averages of the ratio of 
ATP bound/protein concentration (from three experiments) were plotted in the histogram. The 
error bars reflect standard deviations. 
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FIGURE S3: Competition with excess unlabeled nucleotides: Photoadduct formation between 
DrrA and [α-32P] ATP was carried out as described in the legend to Figure 2. The proteins were 
resolved by SDS-PAGE on 10% gels, followed by autoradiography. Lanes 1, 4, 7, 10, and 13-
10µM unlabeled ATP; lanes 2, 5, 8, 11, and 14-100µM unlabeled ATP; lanes 3, 6, 9, 12, and 15- 
500µM 
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FIGURE S4: Quantitation of the ratio of cross-linked dimer/monomeric DrrA protein: The 
data shown in Figure 7 were quantitated. The averages of the ratio of cross-linked 
dimer/monomeric DrrA (from three experiments) were plotted in the histogram. The error bars 
reflect standard deviations. 
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FIGURE S5: Quantitation of the ratio of cross-linked dimer/monomeric DrrA protein: The 
data shown in Figure 5 were quantitated. The averages of the ratio of cross-linked 
dimer/monomeric DrrA (from three experiments) were plotted in the histogram. The error bars 
reflect standard deviations. 
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CHAPTER III 
 
 
 
Role of FtsH and GroEL in the Biogenesis of the  
DrrAB efflux pump 
 
  114 
 
ABSTRACT 
Streptomyces peucetius produces two anticancer agents, doxorubicin and daunorubicin, that 
belong to the anthracycline family of antibiotics.   The organism is self-resistant to the potent 
effects of the antibiotics it produces due to the action of an efflux pump, DrrAB.  The 
doxorubicin efflux pump is made up of two components: DrrA and DrrB.  It has been shown that 
the two proteins are dependent on each other for stability and function.  DrrB when expressed by 
itself (when DrrA is not simultaneously present) is rapidly degraded by a protease.  Several 
known AAA metalloproteases have been known to degrade misassembled membrane proteins 
The goal of the present study is to determine the protease that is involved in the degradation of 
DrrB.  This is expected to provide information about the biogenesis of the complex. Recent 
studies in this laboratory have shown that GroEL may also play a role in the biogenesis of the 
DrrAB complex.  The present study investigates the role of FtsH and GroEL in the biogenesis of 
the DrrAB complex.   
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INTRODUCTION 
Streptomyces peucetius produces two anticancer agents, doxorubicin and daunorubicin, that 
belong to the anthracycline family of antibiotics.   The organism is self-resistant to the potent 
effects of the antibiotics it produces due to the action of an efflux pump, DrrAB (1, 2).   The 
antibiotic synthesis and resistance genes are clustered together in the dnr operon (1).   The 
doxorubicin efflux pump is made up of two components: DrrA and DrrB (2).   The drrAB genes 
have been cloned into the heterologous E.  coli expression system.   Preliminary studies to 
determine the function and stability of the proteins in the expression system indicate that DrrA 
and DrrB are in their proper conformation (2-5).   It has been shown that the two proteins are 
dependent on each other for stability and function (3).   A Western blot analysis of cells 
containing the drrB gene alone shows a drastic reduction in the level of the DrrB protein (Figure 
1, lane 3), implying that DrrA is required for stable expression of DrrB. When DrrA is 
introduced into the cells in trans, the expression level of DrrB is restored (lane 5).   This suggests 
that DrrB depends on DrrA for maintaining its stability.   Levels of DrrA are also reduced in 
cells containing the drrA gene alone, but not as dramatically as DrrB alone (lane 1 and 2).   
However, no ATP binding to DrrA is detected in cells containing DrrA alone, suggesting that 
DrrA is dependent on DrrB for maintaining its active conformation (3).   The co-dependence of 
DrrA and DrrB on one another suggests biochemical coupling between the two proteins.   
Chemical cross-linking studies have shown that the two proteins interact with each other to form 
a tetramer with a stoichiometry of DrrA2B2.    
 
 
 
 
 
  116 
 
 
 
 
 
 
 
J BIOL CHEM, (1998).  273, 17933-17939 
FIGURE 1: Effect of co-expression of DrrA and DrrB.  E.  coli cells, co-transformed with 
pDX103 and pDX108, were induced with IPTG and lysed as described under 
"Experimental Procedures”.  The total lysates were analyzed by SDS-PAGE followed by 
Western blot analysis using anti-DrrA or anti-DrrB serum.  Lane 1, pDX108; lane 2, 
pDX102; lane 3, pDX103; lane 4, pDX101; lane 5, pDX103 and pDX108. 
 
 It has been observed previously that the accumulation of DrrB in the absence of DrrA 
(by gene fusions or expression from a strong promoter) can inhibit the growth of E.coli cells 
(Figure 2, curve with filled circles) (2).  When DrrB is in complex with DrrA, no negative effect 
on growth is seen indicating that DrrA is able to stabilize DrrB and together they are able to form 
a healthy complex (Figure 2, open circles).  Several known AAA metalloproteases have been 
known to degrade misassembled membrane proteins.  Degradation of unassembled SecY (when 
SecE is absent), a subunit of the protein translocase, as well as the subunit ‘a’ of the Fo subunit of 
the H+- ATPase has been shown to be brought about by FtsH.  (6, 7).  The goal of the present 
study is to determine the protease that is involved in the degradation of DrrB. 
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FIGURE 2: Effect of induction of ArsD-DrrA or ArsD-DrrB fusion proteins.  E.coli cells 
containing the indicated plasmids were grown to exponential phase andinduced with 10 
mM sodium arsenite.  Growth was monitored by recording the OD600 of the cultures.  
Triangles: DrrAB in cis; Empty circles: DrrA only; Filled circles: DrrB only. 
 
Recent studies in this laboratory have shown that GroEL may play a role in the 
biogenesis of the DrrAB complex.  It was found that when DrrA was purified by itself from the 
soluble fraction, it co-purifies with GroEL.  GroEL did not co-purify with the complex of 
DrrAB.  GroEL may have an important role to play in the folding state of the DrrA protein and in 
the overall assembly of the DrrAB pump.   This molecular chaperone is believed to play a variety 
of roles, which include promoting folding, assembly, secretion, or membrane insertion of 
proteins (8).  The present study investigates the role of GroEL in the biogenesis of the DrrAB 
complex.    
To overcome the challenges in purification and reconstitution of the DrrA and DrrB 
proteins, it has become an important objective in this laboratory to study the factors involved in 
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stability, folding and and assembly of the DrrAB complex.   This chapter involves the 
determination of the accessory proteins in the biogenesis of DrrAB, mainly, the protease/s 
involved in the degradation of DrrB and the role of GroEL in the assembly of the transporter. 
 
 
 
  119 
EXPERIMENTAL PROCEDURES 
Bacterial Strains and Plasmids:  The bacterial strains are TG1, HMS174, SG110 (lon-) 
ARK797 (ftsH-), ARK796 (ftsH+), MC4100 (GroEL+) and NRK117 (GroEL-).  Plasmids used 
in this study are described below. 
 
PLASMID GENOTYPE 
pDX101 PlacdrrAB in pSU2718 
pDX103 PlacdrrB in pSU2718 
pUC18drrAB PlacdrrAB in pUC18 
pDX203 PlacdrrB in pUC18 
pDXFtsH PlacftsH in pSU2718 
pUCFtsH PlacftsH in pUC18 
pDXGroEL PlacgroEL in pSU2718 
pKYGroEL/ES PlacPgroEgroEL/ES in pSU2718 
 
Media and Growth conditions:  The cells were grown in LB medium at 37oC (9), unless 
mentioned otherwise.    Chloramphenicol was added to 20 µg/ml, kanamycin was added to 30 
µg/ml, ampicillin was added to 100 µg/ml, and tetracycline was added to 15 µg/ml, where 
needed. 
DNA manipulations: The conditions for plasmid isolation, DNA endonuclease restriction 
analysis, ligation, and sequencing have been described elsewhere. 
Construction of site-directed mutations in ftsH:  ftsH mutants were constructed by site-directed 
mutagenesis using a strategene QuikChange multisite-directed mutagenesis kit (La Jolla, CA).    
  120 
The strategy involved the use of complimentary primers that incorporated the change at the 
required position.    The templates used included pUC18ftsH and pSU2718 ftsH, and the 
primers were designed as described earlier (4).   Based on published data (10, 11), the 
conserved lysine residue at position 198 in the Walker A domain of ftsH was altered to 
arginine (K198R) and the conserved glutamate residue at position 415 in the Zn2+ binding 
motif was altered to glutamine (E415Q) respectively.   All mutations were verified by 
nucleotide sequencing. 
Growth experiments using protease- deficient strains: The effect of DrrAB and DrrB protein 
expression on the growth of protease deficient strains (AR797, ftsH-; SG110, lon-; SG1126, 
clpA- and AD1089, clpP-) was analyzed. Different strains containing the appropriate plasmid 
were grown at 30oC followed by induction at mid-log phase with 0.25mM 
isopropylthiogalactopyranoside (IPTG).   Following induction, the samples were immediately 
shifted to 42oC.   Cell growth was monitored by measuring the O.D at 600nm at 0, 1, 2 and 3 
hours after induction. 
Effect of FtsH on DrrAB and DrrB protein expression: Growth and induction of AR797 (ftsH-) 
and ARK796 (ftsH+) strains containing the indicated plasmids was carried out as described in 
the previous section. Cells were collected at 3 hours after switch to 42oC.   The cells were spun 
down and resuspended in 1.5 ml QAE buffer (25 mM Tris.Cl, pH 8.0, 20% glycerol, 2 mM 
EDTA) containing 1 mM DTT and lysed by a single passage through a French pressure cell at 
20,000 psi.    The cell lysates were then centrifuged at 10,000 g for 15 minutes to remove 
unbroken cells.    The supernatant was centrifuged at 100,000 g for 1 hour to prepare 
membrane protein.   50 µg of membrane protein of the reaction mixture was then analyzed by 
SDS-PAGE using a 10% polyacrylamide gel, followed by Western blot analysis using either 
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anti-DrrA or anti-DrrB antibodies.  Similar studies were done using wild-type TG1 cells 
containing the indicated plasmids.   Growth and induction were done at 37oC unless mentioned 
otherwise.  Levels of DrrAB and DrrB were analyzed as mentioned above.   
Co-purification of GroEL and solubilized fraction of DrrA: Purification DrrA in complex with 
DrrB and DrrA alone: DrrAB proteins were purified using pDx121, which introduces his-tags at 
the N-terminus of DrrA and the C-terminus of DrrB.   DrrA was purified using pDX132, which 
introduces a his-tag at the N terminus of DrrA.   HMS174 cells containing the indicated plasmid 
were induced with IPTG.   Membrane and cytosolic fractions were prepared, as described above.   
DrrA protein was purified from the cytosolic fraction by using a Ni-NTA column, while the 
DrrAB proteins were solubilized from the membrane fraction and purified as a complex using 
Ni-NTA.   5 mg membrane protein was solubilized in 5ml buffer containing Buffer A(75mM 
KPi pH 7.4, 200mM NaCl, 20%Glycerol) containing 1mM DTT, and 1X Protease Buffer and 1% 
n-OG. Reaction was incubated for 1 hr on ice. The solubilized reaction was ultracentrifuged for 1 
hr and loaded onto a Ni-column that was pre-equilibrated with 2 column volumes (20 ml) of 
freshly prepared Buffer B (75mM KPi pH 7.4, 200mM NaCl, 20 % Glycerol and 0.05% n-OG) 
followed by incubation for 1hr at 4oC. The column is washed with 3 column volumes (30 ml) of 
Buffer B containing 10mM Imidazole and eluted with Buffer A (75mM KPi pH 7.4, 200mM  
NaCl, 20% glycerol ) containing 1% n-OG and 500mM  Imidazole. 20µl of the sample was 
resuspended in 5µl 4X Laemmli sample buffer and solubilized by heating at 55oC for 10 min. 
The samples were analyzed by SDS-PAGE followed by Western blot analysis with anti-DrrA or 
anti-DrrB antibodies. 
Identification of the unknown 68 kDa protein by amino acid sequencing: The purified DrrA 
protein samples were run on a 10% polyacrylamide gel for electrophoresis.   The 68 kDa protein 
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band was transferred onto a polyvinylidene difluoride membrane.   The band was excised and 
subjected to N-terminal sequencing using a Beckman model LF3000 solid phase amino acid 
sequencer in the core facility of the Department of Biology at the Georgia State University.   
Following identification, the protein samples were separated by electrophoresis followed by 
western blot analysis using anti-DrrA and anti-GroEL antibodies. 
Effect of GroEL/ES on DrrAB and DrrB expression: The expression of proteins was analyzed 
by growth of NRK117 (groEL-) and MC4100 (groEL+) strains containing the indicated 
plasmids at 37oC to a mid-log phase followed by induction at mid-log phase with 0.25mM 
isopropylthiogalactopyranoside (IPTG).   Samples were collected at 3 hours post induction.   
The cells were spun down and resuspended in 1.5 ml QAE buffer (25 mM Tris.Cl, pH 8.0, 
20% glycerol, 2 mM EDTA) containing 1 mM DTT and lysed by a single passage through a 
French pressure cell at 20,000 psi.    The cell lysates were then centrifuged at 10,000 g for 15 
minutes to remove unbroken cells.    The supernatant was centrifuged at 100,000 g for 1 hour 
to prepare membrane protein.   50 µg of membrane protein of the reaction mixture was then 
analyzed by SDS-PAGE using a 10% polyacrylamide gel, followed by Western blot analysis 
using either anti-DrrA or anti-DrrB antibodies.  To study the effect of GroEL on DrrAB or 
DrrB alone, in the presence or absence of FtsH, studies were done with the wild-type (AR796) 
and ts mutant strains (AR797) of FtsH.  Cells containing plasmid containing drrAB or drrB 
were co-transformed with a plasmid carrying groEL.  Cells were grown to a mid-log phase 
followed by induction at with 0.25mM isopropylthiogalactopyranoside (IPTG).   Following 
induction, the samples were immediately shifted to 42oC.  Levels of DrrAB and DrrB were 
analyzed as mentioned above. 
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RESULTS 
Effect of expression of DrrAB or DrrB protein on growth of protease deficient strains:  
Plasmids carrying drrAB (pDx101) and drrB (pDx103) genes were transformed into different 
strains of E.coli carrying mutations for known proteases, namely ftsH (12-14), lon (15), clpA 
(16) and clpP (17).   Cells were grown to exponential phase and induced with IPTG, followed 
by a temperature shift to 42o C to inactivate FtsH.   Optical Density (O.D) of cells was 
measured for 3 hours following induction as an indication of growth.   Results show that while 
lon, clpA and clpP protease deficient strains showed no inhibition of growth (data not shown), 
ftsH- strains showed an inhibition of growth (Figure 3).   Results in Figure 3A show that cells 
expressing DrrB proteins alone as well as cells expressing DrrAB showed significant inhibitory 
effect on growth.   Over-expression or the misassembly of membrane proteins has been shown 
to be harmful or toxic to the growth of cells in other studies (18, 19).   Expression of DrrB in a 
protease-deficient strain might have a similar effect.   Previous studies showed that when DrrB 
is in complex with DrrA, no negative effect on growth is seen indicating that DrrA is able to 
stabilize DrrB and together they are able to form a complex (2).   Our results were therefore 
unexpected i.e.  the growth defect in the ftsH- strain caused by over-expression of the DrrAB 
complex.   This might indicate that 1) the temperature shift to 42 oC might have destabilized 
the proteins, consequently causing the complex to come apart or become misassembled, or  2) 
FtsH in addition to degrading membrane proteins may play an additional role in the chaperone 
activity of the DrrAB transporter (12, 14, 20, 21).   The growth experiment was also performed 
with FtsH+ and FtsH- containing drrAB (pDx108) and drrB (pDx203) cloned in pUC18 over-
expressing plasmid.   Different results were observed in this case (compare figures 3A and 3B).   
While cells expressing DrrAB together (Figure 3B) grew normally, only the cells expressing 
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DrrB protein alone (Figure 3B) showed significant inhibitory effect on growth. Since strains 
containing both pSU2718 and pUC18 clones were upshifted at 42oC, this rules out the 
temperature shift as being the reason for growth inhibitory phenotype seen in pSUdrrAB 
(pDX101). If FtsH is also required for assembly of DrrAB complex, then why DrrAB protein 
expression from pUC18 plasmid did not cause growth inhibition? It is possible that the over-
expression of DrrAB from pUC18 (a very high copy number plasmid) results in a different 
conformation, e.g. Inclusion body formation of the proteins, which may not cause growth in 
hibition.   
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FIGURE 3: Growth analysis of FtsH-deficient strain expressing the drrAB or drrB genes.  
Growth curve analysis was conducted as mentioned under “Experimental procedures”.  Cells 
were grown at 30oC to a mid-log phase followed by induction at mid-log phase with 0.25mM 
IPTG.   Following induction, the samples were immediately shifted to 42oC.  A600 of the cells 
containing various were recorded after induction at 1 hour intervals for 3 hours. 
Fig 3A: Growth analysis in ftsH- strains expressing drrAB or drrB from a low-copy number 
plasmid (pSU2718).  Fig 3B: Growth analysis in ftsH- strains expressing drrAB or drrB from a 
high-copy number plasmid (pUC18). 
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To further establish the role of FtsH in DrrAB expression, we examined whether 
overproduction of FtsH could alleviate the growth defect in FtsH depleted cells caused by 
DrrAB or DrrB.   FtsH gene from E.coli was cloned into pUC18 and pSU2718 plamids.   FtsH 
was co-expressed with DrrAB or DrrB in the FtsH depleted strains.   Results observed in 
Figure 4A or 4B indicate, that overproduction of FtsH can alleviate the growth defect in FtsH 
depleted cells containing DrrAB and/or DrrB. 
A                                                                         B 
    
 
FIGURE 4: Growth analysis of AR796 (ftsH+) and deficient AR797 (ftsH -) strains 
expressing drrAB or drrB along with ftsH.   
Growth analysis was conducted as mentioned under “Experimental procedures”.  Cells were 
grown at 30oC to a mid-log phase followed by induction at mid-log phase with 0.25mM IPTG.   
Following induction, the samples were immediately shifted to 42oC.  A600 of the cells 
containing various were recorded after induction at 1 hour intervals for 3 hours. 
A   pSUdrrAB (pDX101) or pSUdrrB (pDX103) in combination with pUCftsH. 
B pUCdrrAB (pDX108) or pUCdrrB (pDX203) in combination with pSUftsH.   
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Effect of FtsH expression on levels of DrrAB: To further characterize the effect of FtsH on the 
levels of DrrAB, 50 ml of cells from the above growth curve experiments were harvested at 2 hr 
post induction and membrane proteins were prepared.   Western blot analysis of 50 µg 
membrane protein was carried out with either anti-DrrA or anti-DrrB antibodies.  The expression 
of DrrA and DrrB from pSUdrrAB (pDX101) in ARK796 (ftsH+) was less (Figure 5A, lane 1) as 
compared to levels of DrrA and DrrB from pSUdrrAB in AR797 (ftsH-) (Figure 5A, lane 3).   
Similar results were obtained when pUCdrrAB (pDX108) were expressed in ARK796 (ftsH+) 
(Figure 5B, lane 1) and AR797 (ftsH-) (Figure 5B, lane 3).   The data suggest that the DrrAB 
proteins accumulate in the absence of FtsH, thus resulting in toxic effect to the cells.    When 
FtsH was over-expressed from a plasmid along with DrrAB in the FtsH depleted strains, the 
levels of DrrA and DrrB in either plasmid combination (Figure 5A, lanes 2 and 4 and 5B, lanes 2 
and 4) were significantly decreased in either strain (ARK796 (ftsH+) or AR797 (ftsH-)).  These 
data further indicates that FtsH is involved in degradation of DrrA and DrrB.   
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FIGURE 5: Effect of FtsH on expression levels of DrrAB  
 
AR796 and AR797 cells containing the appropriate plasmid/s were grown at 30oC to mid-log 
phase followed by induction with 0.25mM IPTG.   Following induction, the samples were 
immediately shifted to 42oC.  Membrane fraction was prepared as described in “Experimental 
Procedures”.   50 µg membrane protein was analyzed by 10% SDS-PAGE, followed by 
Western blot using anti-DrrA and anti-DrrB antibodies.    
Fig 5A: Lanes 1, AR796/pSUAB; Lane 2, AR796/pSUAB/pUCFtsH; Lane 3, AR797/pSUAB; 
Lane 4, AR797/pSUAB/pUCFtsH.   
Fig 5B: Lanes 1, AR796/pUCAB; Lane 2, AR796/pUCAB/pSUFtsH; Lane 3, AR797/pUCAB; 
Lane 4, AR797/pUCAB/pSUFtsH 
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Effect of FtsH expression on expression levels of DrrB:  When DrrB was expressed in the 
absence of DrrA, the level of DrrB from pUCdrrB (pDX203) in ARK796 (ftsH+) was much 
less (Figure 6A, lane 1) as compared to pUCdrrB in AR797 (ftsH-).  Accumulation of high 
levels of DrrB in FtsH- strain confirms that FtsH is involved in the degradation of DrrB.The 
above data confirms that FtsH is involved in the degradation of DrrB.  In addition, it suggests 
that DrrA may regulate the synthesis of DrrB so that in the absence of DrrA, high levels of 
DrrB accumulated due to unregulated expression 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6: Effect of FtsH on expression levels of DrrB in the absence of DrrA  
 
AR796 and AR797 cells containing the appropriate plasmid were grown at 30oC to a mid-log 
phase followed by induction at mid-log phase with 0.25mM IPTG.   Following induction, the 
samples were immediately shifted to 42oC.  Membrane fraction was prepared as described in 
“Experimental Procedures”.   50 µg membrane protein was analyzed by 10% SDS-PAGE 
followed by Western blot using anti-DrrB antibodies.   Lanes 1, AR796/pUCB- 1 hr induction; 
Lane 2, AR796/pUCB- 2 hr induction; Lane 3, AR796/pUCB- 3 hr induction; Lane 4, 
AR797/pUCB- 1 hr induction; Lane 5, AR797/pUCB- 2 hr induction; Lane 6, AR797/pUCB- 3 
hr induction. 
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Suppression of growth defect by the over expression-of GroEL: We further tested whether over 
expression of GroEL was able to restore the growth defect caused by DrrAB or DrrB in FtsH- 
depleted strains.  GroEL gene from E.coli was cloned into pSU2718 plamid.   GroEL was co-
expressed with DrrAB or DrrB in the FtsH-depleted strains.   Results in Figure 7A (pSUdrrAB or 
pSUdrrB in combination with pUCGroEL) indicate that overproduction of FtsH can alleviate the 
growth defect in FtsH-depleted cells expressing DrrB.  Studies with alkaline phosphatase that 
was fused to the SecY membrane protein have shown that the growth defect and the abnormal 
translocation of alkaline phosphatase in ftsH mutant strains can be suppressed by the 
overproduction of the molecular chaperone Hsp90 (22).  Thus, FtsH may have an additional 
chaperone-like activity that has been proposed for other AAA ATPases (23-26). 
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FIGURE 7: Growth analysis of wild-type FtsH (AR796, ftsH+) and deficient FtsH (AR797, 
ftsH -) strains simultaneously expressing two genes, drrAB or drrB along with wild type 
groEL.   
Growth curve analysis was conducted as mentioned under “Experimental procedures”.  Cells 
were grown at 30oC to a mid-log phase followed by induction at mid-log phase with 0.25mM 
IPTG.   Following induction, the samples were immediately shifted to 42oC.  A600 of the cells 
containing various were recorded after induction at 1 hour intervals for 3 hours. 
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Role of FtsH as a chaperone for DrrAB: Construction of FtsH mutants in the AAA domain and 
the HExxH domain: To study the role of FtsH as a potential chaperone for DrrAB assembly, 
mutants in the ATPase domain (K198R) and the protease domain (E415Q) of ftsH were 
constructed within the plasmid containing the ftsH gene.    In ATP-dependent proteases, Lon 
(26) and YmeI (24), a mutation in the conserved lysine residue of the ATPase domain was 
found to prevent chaperone function while retaining the protease function, and a mutation in 
the glutamine residue of the protease domain abolished proteolytic activity while maintaining 
the chaperone activity of the protease.    Similar mutants constructed in FtsH by two groups 
show contradictory results.   Ito’s group  (10) has shown that the glutamine mutation in the 
proteolytic domain retained the proteolytic function of the protein   while Holler’s group (11) 
have shown that the mutation completely lacks protease activity.   In this study, the FtsH 
mutants (K198R and E415Q) were co-expressed with DrrAB or DrrB in the FtsH- strains.   Our 
results show that the mutation in the proteolytic domain (E415Q) of FtsH was able to restore 
the growth defect caused by DrrAB or DrrB in FtsH depleted strains, while a mutation in the 
ATPase domain (K198R) was unable to restore the growth defect in these strains.    
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FIGURE 8: Growth analysis of AR796 (ftsH+ ) and AR797 (ftsH -) strains expressing 
drrAB or drrB along with wild type ftsH or its mutants FtsHK198R and FtsHE415Q.   
Growth analysis was conducted as mentioned under “Experimental procedures”.  Cells were 
grown at 30oC to a mid-log phase followed by induction at mid-log phase with 0.25mM IPTG.   
Following induction, the samples were immediately shifted to 42oC.A600 of the cells 
containing various were recorded after induction at 1 hour intervals for 3 hours. 
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Effect of FtsH mutants on levels of DrrA and DrrB: The levels of DrrA and DrrB in the above 
mutants were analyzed.   Differences in the levels of DrrA and DrrB accumulation indicate that 
the K198R, a mutation in the ATPase domain of FtsH, also abolished the proteolytic function 
(Figure 9, lane 5 and 6), thereby causing the accumulation of DrrA and DrrB, and growth 
inhibition seen in Figure 8. The E415Q mutant lost about 75% of its proteolytic function 
(Figure 9, lane 7 and 8) resulting in accumulation of 1/4th the amount of DrrA and DrrB 
proteins.   From the above data, no conclusions could be made on the chaperone effect of FtsH, 
since the E165Q mutant still retains potential protease activity.   Thus restoration of growth 
seen in Figure 8 would result from either chaperone effect of the functional AAA domain or  
due to proteolysis of DrrAB proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 9: Effect of FtsH mutants on expression levels of DrrAB in wild type E.coli TGI 
cells.  
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TG1 cells containing the indicated plasmids were grown at 37oC to a mid-log phase followed 
by induction at mid-log phase with 0.25mM IPTG.   Following induction, the samples were 
incubated for 3 hrs at 37oC.  Membrane fraction was prepared as described in “Experimental 
Procedures”.   50 µg membrane protein was analyzed by 10% SDS-PAGE followed by 
Western blot using anti-DrrA and anti-DrrB antibodies.   Lanes 1-2, pUCAB/ pSU2718; Lanes 
3-4, pUCAB/ pSUFtsH; Lanes 5-6, pUCAB/ pSUFtsHK198R; Lanes 7-8, pUCAB/ 
pSUFtsHE415Q.   
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Effect of FtsH on misassembled or over expressed DrrAB proteins: To further examine the 
degradative effect of FtsH on the DrrAB complex, wild-type E.coli cells were co-transformed 
with plasmids carrying drrAB and ftsH genes.   Following induction, cells were grown  for an 
additional 3 hours at 37oC and not at 42oC as with the previous experiments performed with  
ARK796 (ftsH+) or AR797 (ftsH-) strains.   Results in Figure 10A, (where DrrAB was 
expressed on a low copy number plasmid, pSU2718), show that FtsH has no degradative effect 
on DrrAB when expressed in low copy numbers at 37oC.   However, when the temperature was 
shifted to 42oC soon after induction (Figure 10B), FtsH degraded DrrB as indicated by the 
complete loss of protein in this situation.   When DrrAB was expressed on a high copy number 
plasmid, pUC18, FtsH degraded the over-expressed proteins even at 37oC induction (Figure 
10C, lanes 3 and 4). Thus FtsH may play a crucial role in quality control and biogenesis of the 
DrrAB complex by removing improperly assembled DrrB or DrrAB protein. These results 
show that expression of DrrAB from a low copy number plasmid results in proper assembly of 
the complex, which is not susceptible to cleavage by FtsH (Figure 10A). However, expression 
from a high-copy number plasmid (pUC18) results in improper assembly and these proteins are 
targeted by FtsH (Figure 10C).  
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FIGURE 10: Effect of FtsH on misassembled proteins 
TG1 cells containing the appropriate plasmid/s were grown at 37oC to a mid-log phase 
followed by induction at mid-log phase with 0.25mM IPTG.   Following induction, the 
samples were incubated for 3 hrs at 37oC.  Membrane fraction was prepared as described in 
“Experimental Procedures”.   50 µg membrane protein was analyzed by 10% SDS-PAGE 
followed by Western blot using anti-DrrA and anti-DrrB antibodies.   
Fig 10A: Lanes 1 and 3, pSUAB/ pUCFtsH; Lanes 2 and 4, pSUAB/ pUC18.    
Fig 10B: Lane 1, pSUAB/ pUCFtsH induced for 2 hrs at 30oC; Lane 2, pSUAB/ pUCFtsH 
induced for 2 hrs at 42oC. 
 Fig 10C: Lanes 1 and 3, pUCAB/ pSUFtsH; Lane 2 and 4, pUCAB/ pSU2718. 
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Co-purification of DrrA and GroEL:  During the purification of soluble DrrA containing an 
his-tag at the N terminus, a 68 kDa protein co-purified along with DrrA.  N-terminal amino 
acid sequencing followed by immunoblotting with anti-GroEL identified the 68 kDa protein to 
be GroEL.  GroEL does not co-purify with the complex of DrrAB (data not shown).  These 
indicate that GroEL might have a role in the assembly of DrrAB. 
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FIGURE 11: Purification of DrrA 
His-tagged DrrA protein was purified from HMS174 cells containing only drrA gene on the 
plasmid pDX132.  The total cell lysate was loaded onto a Ni-column and eluted with different 
concentrations of imidazole.  50ug protein was loaded on a 12% SDS-PAGE gel for 
electrophoresis.  Lane 1, total lysate; lane 2, unbound; lane 3 100mM imidazole elution; lane 4, 
20mM imidazole elution; lane 5, 500mM imidazole elution.  The western blot analysis was 
carried out buy using anti-DrrA or anti-GroEL antibodies. 
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Effect of a GroEL ts mutation on expression of DrrAB:  To characterize the role of GroEL, we 
used a strain with a ts mutation in GroEL.  The effect of this mutation on levels of DrrA and 
DrrB in vivo was determined.  Data in Figure 12A show that the levels of DrrA and DrrB were 
severely affected in this mutant background.  Over production of GroEL in the ts strain 
restored normal levels of DrrA and DrrB.  The above data indicate that GroEL is essential for 
their expression or assembly, and that unassembled protein in the absence of GroEL might be 
degraded by FtsH. 
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FIGURE 12: Effect of GroEL ts mutations on expression of DrrAB:  
TG1 cells containing the indicated plasmids were grown at 37oC to a mid-log phase followed 
by induction with 0.25mM IPTG.   Following induction, the samples were incubated for 1.5 
hrs and 3 hrs at 37oC.  Membrane fraction was prepared as described in “Experimental 
Procedures”.   50 µg membrane protein was analyzed by 10% SDS-PAGE followed by 
Western blot using anti-DrrA and anti-DrrB antibodies.    
Fig 12A: Lanes 1-2, GroEL+/pUC18 ; Lanes 3-4, GroEL+/pUCAB; Lanes 5-6, GroEL-/pUC18; 
Lanes 7-8, GroEL-/pUCAB. Samples were induced for 1.5 hrs and 3 hrs respectively.  
Fig 12B: Lanes 1-2, GroEL-/pUC18; Lanes 3-4, GroEL-/pUCAB; Lanes 5-6, GroEL-
/GroEL/ES/pUC18; Lanes 7-8, GroEL-/GroEL/ES/pUCAB. Samples were induced for 1.5 hrs 
and 3 hrs respectively. 
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GroEL (pSUgroEL) was co-expressed with DrrAB (pDX108) or DrrB only (pDX203) in 
ARK796 (ftsH+) or AR797 (ftsH-) and the levels of DrrA and DrrB proteins were analyzed.   
Interestingly, we see that the levels of DrrA and DrrB were reduced in ARK796 (ftsH+) strains 
while the levels of DrrA and DrrB seemed to be stable in ARK797 (ftsH-) cells (Figure 13B).   
when GroEL was over-expressed in these strains. On the other hand, levels of DrrB when 
expressed alone were reduced in both ARK796 and ARK797 strains (Figure 13A). These 
results imply that GroEL and FtsH may function together in proteolysis and biogenesis of 
DrrAB. The effect of GroEL seems to promote proteolysis of DrrB by FtsH (Figure 13 A and 
B), or by another unknown protease as seen in Figure 13A, lane 3-4). 
 
                                 A 
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FIGURE 13: Effect of GroEL on DrrAB and DrrB protein levels in wild-type or FtsH 
deficient strains: 
AR796 and AR797 cells containing the appropriate plasmid/s were grown at 30oC to a mid-log 
phase followed by induction at mid-log phase with 0.25mM IPTG.   Following induction, the 
samples were immediately shifted to 42oC.  Membrane fraction was prepared as described in 
“Experimental Procedures”.   50 µg membrane protein was analyzed by 10% SDS-PAGE 
followed by Western blot using anti-DrrA and anti-DrrB antibodies.    
Fig 13A: Lane 1, AR796/pUCB/pSU2718; Lane 2, AR796/pUCB/pSUGroEL; Lane 3, 
AR797/pUCB/pSU2718; Lane 4, AR797/pUCB/pSUGroEL.   
Fig 13B: Lane 1, AR796/pUCAB/pSU2718; Lane 2, AR796/pUCAB/pSUGroEL; Lane 3, 
AR796/pUCAB/pKYGroEL/ES; Lane 4, AR797/pUCAB/pSU2718; Lane 5, 
AR797/pUCAB/pSUGroEL; Lane 6, AR797/pUCAB/pKYGroEL/ES. 
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DISCUSSION 
 With the goal of finding out which protease in particular cleaves DrrB, when DrrA is not 
simultaneously present, we procured ftsH (14), lon (15) , clpA (16) and clpP (17) deficient 
strains from Dr. Ito in Japan.   We have seen before that stabilization of DrrB in the absence of 
DrrA could become inhibitory to the growth of the cells (2).   Expression of DrrB in a 
protease-deficient strain might have a similar effect.   Initial growth analysis of the protease- 
deficient strains expressing DrrAB or DrrB indicated that FtsH may be the protease involved in 
the degradation of DrrB.    Wild-type FtsH co-expressed in FtsH-depleted strains containing 
DrrB was found to suppress the growth defect.   Wild-type GroEL co-expressed in FtsH-
depleted strains containing DrrB was also found to suppress the growth defect.   An analysis of 
levels of proteins in these strains showed that in the absence of FtsH, DrrB alone was found to 
accumulate in very large quantities indicating that FtsH is involved in degradation of DrrB.   In 
FtsH-depleted cells expressing both DrrA and DrrB together, an accumulation of both proteins 
was seen, however, DrrB did not accumulate as much as when it was expressed alone in the 
absence of DrrA.   There may be a possibility that DrrA regulates the synthesis of DrrB so that 
in the absence of DrrA, high levels of DrrB accumulated due to unregulated expression.   FtsH 
functions as a quality control protein, which degrades over-expressed proteins as well as 
misassembled or unfolded proteins as experimentally verified in Figure 10.   FtsH is a Zn-
dependent metalloprotease that belongs to a subfamily of the AAA family of ATPases (14).   It 
is an inner membrane protein that is generally involved in membrane functions, especially 
proteolysis of improperly assembled proteins.   Degradation of unassembled SecY (when SecE 
is absent), a subunit of the protein translocase (6), as well as the subunit ‘a’ of the Fo subunit of 
the H+- ATPase (7) has been shown to be brought about by FtsH.   This is similar to the 
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situation with DrrB when DrrA is not available or when proteins are over-expressed or 
misassembled.   
Proteases from the AAA ATPases family, for example, (Clp (25), Yta10 and Yta12 (23) 
homologs of FtsH, Lon (26) and YmeI (24) )have been demonstrated to have a chaperone-like 
role independent of proteolysis.  While our preliminary data tended towards a possible role of 
FtsH on the DrrAB complex, our initial experiments with FtsH mutants were inconclusive.  We 
will continue to explore the possibility of FtsH having a chaperone-like role by constructing 
mutants that totally lack protease activity but retain the ATPase domain.  If this mutant is able 
to suppress the growth defect of FtsH-depleted strains expressing DrrAB, it would imply that 
FtsH may have an additional chaperone-like role independent of proteolysis. 
Our understanding that GroEL may seem to play a role in the assembly of DrrAB came from 
the purification of His-tagged DrrA protein.   The 60 kDa GroEL protein co-purified with DrrA 
when it was expressed by itself but did not co-purify with the complex of DrrAB.   Data is 
Figure 12A further showed that the levels of DrrA and DrrB are severely affected when 
expressed in a ts mutant GroEL strain, thus indicating that GroEL is essential for the 
expression or assembly of DrrA and DrrB.   When wild-type groEL was expressed in FtsH- 
depleted strains containing DrrB, it was found to suppress the growth defect caused by 
overexpressed DrrB (Figure 12B).   An analysis of the effect of GroEL on DrrA and DrrB 
protein levels in wild-type or FtsH-deficient strains suggested that GroEL may have different 
roles to play in the biogenesis of the DrrAB complex as also shown in the model illustrated in 
the model below.    
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FIGURE 14: Model illustrating the role of GroEL and FtsH in the biogenesis of DrrA 
and DrrB protein.   
When DrrB protein was expressed in the absence of DrrA, GroEL enhances its degradation in 
the presence or absence of FtsH.   Since we know that FtsH is the major protease that acts on 
DrrB, therefore in its absence, GroEL may be recruiting another protease for degradation of 
DrrB. When DrrA and DrrB are expressed together, GroEL may play a dual role depending on 
the presence or absence of FtsH.   In the presence of FtsH, it may enhance the degradation of 
DrrB while in its absence, it may be involved in proper folding and stability of the complex.  
Levels of DrrA are stabilized in either strain indicating that GroEL might help maintain DrrA 
in a partially unfolded state before it is presented to DrrB. 
 It has previously been shown that GroEL plays an important role in the biogenesis of lactose 
permease (LacY) and in secretion of beta-lactamase by keeping it in an unfolded, 
translocation-competent state.   The LacY-GroEL complex can then be post-translationally 
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transferred to the membrane vesicles (8).   Thus, GroEL is believed to play a variety of roles, 
which include promoting folding, assembly, secretion, or membrane insertion of proteins.   The 
data shown here also suggest that GroEL has a role to play in promoting folding of DrrA, 
enhancing degradation of DrrB in the absence of DrrA and perhaps in the assembly of the 
proteins when they are expressed together. 
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DrrA and DrrB proteins of Streptomyces peucetius belong to the ABC family of transporters that 
have been implicated in a number of diseases, such as cystic fibrosis, Tangiers disease and Dubin 
Johnson syndrome, among others (1).  The study of these drug pumps has also become of utmost 
importance with the occurrence of multidrug resistance in human cancer cells and its direct 
correlation with the overexpression of several ABC transporters, namely, P-glycoprotein (Pgp, 
ABC1), multidrug resistance associated protein (MRP1, ABCC2) and breast cancer resistance 
protein (BCRP, ABCG2) (1).  The DrrAB system bears sequence, structural, and functional 
similarities to Pgp (2-4). An understanding of the DrrAB transporter is thus expected to help in 
obtaining a better understanding of the origin and mechanism of action of drug restistant proteins 
such as Pgp. A major question that researchers are posed with is how the nucleotide binding 
domains and the membrane domains interact with one another during the catalytic cycle of the 
transporter. While most ABC transporters, such as Pgp (5), CFTR (6), LmrA (7) and MsbA (8), 
have the nucleotide binding domain and the membrane domain on the same molecule, they are 
present on separate subunits in DrrAB. This unique feature of DrrAB makes it a prototype for the 
study of NBD:TMD and NBD:NBD interactions.   
Previous cross-linking studies in this laboratory employed membrane-permeable and 
impermeable amine to amine cross-linkers, DSP and DTSSP, and identified a complex of DrrA 
and DrrB (9). However, using DSP and DTSSP, it was not possible to easily determine the 
regions involved in cross-linking. In the present study, we have utilized a more direct and 
specific approach to identify the regions in DrrA and DrrB that interact with one another.  DrrB 
protein contains a single cysteine at position 260, whereas DrrA protein contains none. The 
presence of only one cysteine in our system enabled us to use heterobifunctional and 
homobifunctional thiol cross-linkers to probe the interacting sites within each protein.  To 
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identify regions in DrrB that were involved in interaction with DrrA, a cysteine-less DrrB was 
first created by substituting a serine at position C260 by site-directed mutagenesis. Twenty 
single-cysteine substitutions were thus introduced at various positions in the cysteine-less DrrB. 
The location of the cysteine substitutions in DrrB was based on a recently developed topological 
model for DrrB, which suggests that DrrB consists of eight transmembrane domains with both 
the N-terminal and the C-terminal ends of the protein directed in the cytoplasm. To directly 
identify the regions of DrrB that interact with DrrA, a heterobifunctional cysteine to amine 
chemical cross-linking agent, GMBS (N-[-maleimidobutyryloxy]succinimide ester), was 
employed. Our Studies show that DrrA cross-links with both the N-terminal and the C-terminal 
ends of DrrB, suggesting that these two regions may participate in interaction with DrrA. An in-
depth sequence analysis with exporters, including DrrB, LmrA, MDR1, CFTR, and MsbA, as 
well as the importer BtuC allowed us to identify a conserved motif bearing the amino acid 
sequence GE-1..A3R/K..G7 within the N-terminal cytoplasmic tail of DrrB. This analysis led us to 
conclude that this conserved sequence is a modified version of the EAA motif E1AA3RALG7 
previously identified in the interaction interfaces of importers of the ABC family. The present 
study is the first analysis where interacting domains in the membrane component of a drug efflux 
system have been biochemically analyzed by using a cross-linking approach.  
To identify the domains in DrrA involved in interaction with DrrB, several cysteine 
substitutions in and around the conserved domains of DrrA were made in constructs already 
containing a S23C substitution (cysteine in the interacting domain at N-terminal tail of DrrB) in 
DrrB. By using the disulphide cross-linking strategy, we conclude that the Q-loop region 
(cysteines in position Y89 and S91) of DrrA is involved in interaction with DrrB. We also found 
that by placing a cysteine in the Q-loop, DrrA was trapped in the dimeric state, indicating that 
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this region is present at the dimeric interface. Fourier Resonance Energy Transfer (FRET) was 
then carried out to identify the conformation of the dimers. It was found that these dimers were 
arranged in an “head-to-tail” conformation, as seen with other ABC proteins. In the closed 
conformation of NBD’s of MalK (10) and MJO796 (11), the dimers have nucleotides bound at 
their interface. In our study we found that with the addition of a non-hydrolysable ATP analog, 
ATPγS, a stable Y89C DrrA dimer was produced even in the absence of the cross-linker, 
suggesting that in this situation the ATP analog serves to hold the Y89C dimer together.  If 
E165Q, a mutation in the Walker B domain that prevents hydrolysis of ATP, is simultaneously 
present along with Y89C, then either ATP or ATPγS could substitute for the disulfide cross-
linker.  Based on these observations, we can conclude that the Y89C-Y89C contact is sensitive to 
binding of ATP/ATPγS so that the Y89C dimer can be stabilized either by the disulfide cross-
linker acting directly on the Q-loop or by binding of ATPγS to the interface of the dimer.  These 
data imply that the Y89C dimeric conformation indeed resembles the closed state.   
With the use of different arm-length cross-linkers, it was seen that substituting S23 
residue with S23C in DrrB produced a significant effect on the behavior of Y89C in DrrA.  DrrA 
(Y89C) can be cross-linked with linkers varying in length from 0 (CuPhe) to 24 Å (MTS).  
However, when S23C is simultaneously present in DrrB, the results were strikingly different:  
copper and DTME (13.3 Å) can still cross-link DrrA and produce DrrA homodimers very well, 
but MTS was not able to do so.  These data indicate that placing a cysteine in this region of DrrB 
produces a conformational change in the helical domain of DrrA. We propose that the two Y89C 
residues (or the Q-loops) from opposing monomers are in flexible contact until a conformational 
change in DrrB (produced by S23C substitution here) produces a change in DrrA which fixes it 
in one position.  Instead of resulting in opening of the NBD dimer, the result of this interaction 
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between Y89C and S23C seems to be to fix the distance between DrrA monomers at less than 13 
Å.  It seems that the overall effect of this conformation of DrrB is to facilitate the closed 
conformation of DrrA. This is the first biochemical analysis that shows the long-range effects of 
conformational changes in TMD (DrrA) on the NBD (DrrA).  
To further our understanding of the mechanism of the DrrAB complex, we analysed the 
accessory factors involved in the biogenesis of the DrrAB complex, mainly the proteins involved 
in degradation of unstable DrrB (when DrrA is not simultaneously present) and in 
folding/assembly of the protein. Several known AAA metalloproteases have been known to 
degrade misassembled membrane proteins (12, 13). Using various protease deficient-strains, we 
could directly conclude that FtsH, a member of the AAA family of proteases, was involved in the 
proteolysis of DrrB.  Initial data also suggest that FtsH may have an additional chaperone-like 
role in assembly of the DrrAB complex.  Studies are currently underway to demonstrate the 
possible chaperone function of FtsH.  
Finally, we found that GroEL is also essential for the expression or assembly of DrrA and 
DrrB. In a GroEL-defecient strain, stable assembly of the DrrAB complex was not seen. A 
further analysis of effect of GroEL suggests that it may enhance the degradation of DrrB (when it 
is expressed by itself in the absence of DrrA) and may stabilize/maintain the DrrA and DrrB 
proteins when they are expressed together. Studies are underway to characterize a more defined 
role that GroEL may play in the biogenesis of the DrrAB complex.  
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